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ABSTRACT 
Neutralization escape mutant has played an important role in antigenic evolution of 
various virus-causing diseases. DENV, the causative agent of dengue has been shown to 
escape antibody neutralization, thereby causing an epidemic outbreak. The pattern 
through which DENV escape neutralization that leads to antigenic evolution, however, 
has not been thoroughly investigated in hyper endemic countries. It is hypothesized that, 
the highly susceptible DENV demonstrates a clear pattern of antigenic evolution from 
being minor strains (less frequent during an outbreak) to dominant strains (very frequent 
during an outbreak).  This suggests that the minor strains may act as a springboard for 
the emergence of more virulent dominant strains by acquiring some characteristics of 
the minor strains. Hence, the overall objective of the present study is to provide an 
insight into the antigenic evolution of DENV-1 and DENV-2 in Malaysia. To 
investigate this possibility, the present study used truncated DENV-1 and DENV-2 
recombinant E, cloned and expressed on phage M13 g3p attachment protein.  Using 
site-directed mutagenesis, six single mutations were engineered separately onto the 
respective recombinant E gene.  Effects of these mutations on binding to insects and 
mammalian cells were determined in vitro. The polyclonal antibodies generated against 
these recombinant proteins in BALB/c mice were used in microneutralization and Foci 
Reduction Neutralization Test to evaluate neutralizing antibody determinant associated 
with antigenic evolution. Serial propagation in vitro was adopted to handpick the 
neutralization escape mutant in the sub-neutralizing antibody concentration. To evaluate 
potential host where the selection occurs, the escape mutant were adapted to mimic 
mosquito and human cycle in vitro. Finding from the present study shows that two 
mutations (E272 and E390) on DENV-1 E were demonstrated to affect binding of the 
recombinant proteins to C6/36 mosquito and Vero cells. Polyclonal antibodies 
generated against recombinant E272 and E390 proteins exhibited decreased binding to  
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DENV-1 virion. The polyclonal antibodies reduced the number of DENV-1 foci formed 
up to four-folds for the five endemic DENV-1 strains (GIa, GIb, GIc, GII and GIII) 
tested. Two DENV-1 isolates likely to escape neutralization were identified; D1.10245 
(GII) and D1.11177 (GIb). In DENV-2, mutations on E52, E164 and E393 were 
demonstrated to affect binding of the recombinant proteins to C6/36 mosquito and Vero 
cells. Polyclonal antibodies generated in mice against recombinant E52, E164 and E176 
exhibited decreased binding to DENV-2 (Asian 1 strain) and E164 and E335 on one of 
the Cosmopolitan strain. The polyclonal antibodies against E52, E71, E335 and E393 
reduced the number of foci formed up to four-folds for Cosmopolitan DENV-2 strains 
tested. The E52 and E71 substitutions select isolates likely to escape neutralization in 
both Cosmopolitan strain (D2.14245 and D2.1877347) and Asian 1 strain (D2.16041). 
Evidence from the present study show that the neutralization escape strains from 
DENV-1 and DENV-2 alternating between two different hosts adapts differently. The 
observed difference in DENV-1 and DENV-2 on C6/36 and Vero cells was evident in 
the variation in amino acid residues on E. Of these 6 mutations engineered on DENV-1 
and DENV-2 recombinant E, substitution on EDI/EDII junction are likely to facilitates 
antigenic evolution of DENV-1 (E272) and DENV-2 (E52 and E71) in Malaysia. 
Overall, the study identified dominant DENV-1 and DENV-2 strains expected to evolve 
in Malaysian natural population in the future. The antigenic determinants involved were 
identified. The result of the study directly underlines the effects of these mutations on 
naturally emerging DENV-1 and DENV-2 in Malaysian population and its implications 
on dengue affliction and vaccines design. 
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ABSTRAK 
Peneutralan melarikan diri mutan telah memainkan peranan penting dalam evolusi 
antigen pelbagai penyakit virus penyebab. DENV, agen penyebab denggi telah terbukti 
untuk melarikan diri antibodi peneutralan, sekali gus menyebabkan wabak wabak. 
Corak di mana DENV melarikan diri peneutralan yang membawa kepada evolusi 
antigen, bagaimanapun, telah tidak dikaji secara menyeluruh di negara-negara endemik 
hyper. Ia hipotesis bahawa, DENV yang sangat mudah terdedah menunjukkan corak 
yang jelas evolusi antigen daripada menjadi strain kecil (kurang kerap semasa wabak) 
untuk strain dominan (sangat kerap semasa wabak). Ini menunjukkan bahawa strain 
kecil boleh bertindak sebagai batu loncatan untuk kemunculan strain dominan lebih 
getir dengan memperoleh beberapa ciri-ciri strain kecil. Oleh itu, objektif keseluruhan 
kajian ini adalah untuk memberi kefahaman tentang evolusi antigen daripada DENV-1 
dan DENV-2 di Malaysia. Untuk menyiasat kemungkinan ini, kajian ini digunakan 
dipenggal DENV-1 dan DENV-2 rekombinan E, klon dan menyatakan pada faj M13 
g3p lampiran protein. Menggunakan mutagenesis diarahkan tapak , enam mutasi 
tunggal telah kejuruteraan secara berasingan ke gen E rekombinan masing-masing. 
Kesan mutasi pada mengikat kepada serangga dan sel-sel mamalia telah ditentukan 
dalam vitro. Antibodi polyclonal dijana terhadap ini protein rekombinan dalam BALB/c 
tikus telah digunakan dalam microneutralization dan tumpuan Pengurangan Peneutralan 
Ujian untuk menilai meneutralkan penentu antibodi yang berkaitan dengan evolusi 
antigen. Pembiakan bersiri dalam vitro telah diguna pakai untuk memilih dgn rapi 
peneutralan melarikan diri mutan dalam antibodi penumpuan sub- meneutralkan . Untuk 
menilai tuan rumah yang berpotensi di mana pemilihan berlaku, mutan melarikan diri 
telah disesuaikan untuk meniru nyamuk dan kitaran manusia dalam vitro. Dapatan 
kajian ini menunjukkan bahawa dua mutasi (E272 dan E390) pada DENV-1 E telah 
ditunjukkan untuk memberi kesan mengikat satu protein rekombinan untuk C6/36 
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nyamuk dan sel-sel Vero. Antibodi polyclonal dijana terhadap E272 rekombinan dan 
protein E390 dipamerkan menurun mengikat untuk DENV-1 virion . Antibodi 
polyclonal mengurangkan bilangan DENV-1 tumpuan ditubuhkan sehingga empat kali 
ganda dalam tempoh lima endemik DENV-1 strain (GIA, GIB, GIC, GII dan GIII) diuji. 
Dua DENV-1 diasingkan mungkin untuk melarikan diri peneutralan telah dikenal pasti; 
D1.10245 (GII) dan D1.11177 (GIB). Dalam DENV-2, mutasi pada E52, E164 dan 
E393 telah ditunjukkan untuk memberi kesan mengikat satu protein rekombinan untuk 
C6/36 nyamuk dan sel-sel Vero. Antibodi polyclonal dijana dalam tikus terhadap 
rekombinan E52, E164 dan E176 dipamerkan menurun mengikat DENV-2 (Asia satu 
ketegangan) dan E164 dan E335 pada salah satu tekanan yang Cosmopolitan. Antibodi 
polyclonal terhadap E52, E71, E335 dan E393 mengurangkan bilangan tumpuan 
ditubuhkan sehingga empat kali ganda untuk Cosmopolitan DENV-2 strain diuji. E52 
dan E71 penggantian pilih mengasingkan mungkin untuk melarikan diri peneutralan 
dalam kedua-dua strain Cosmopolitan (D2.14245 dan D2.1877347) dan satu ketegangan 
Asia (D2.1604). Bukti-bukti dari kajian menunjukkan hadir bahawa strain peneutralan 
melarikan diri dari DENV-1 dan DENV-2 seli antara kedua-dua kumpulan yang berbeza 
menyesuaikan diri berbeza. Perbezaan diperhatikan dalam DENV -1 dan DENV-2 pada 
C6/36 dan sel-sel Vero terbukti dalam variasi dalam sisa-sisa asid amino di E. Daripada 
6 mutasi kejuruteraan pada DENV-1 dan DENV-2 E rekombinan , penggantian di 
EDI/EDII simpang mungkin memudahkan evolusi antigen daripada DENV-1 (E272) 
dan DENV-2 (E52 dan E71) di Malaysia. Secara keseluruhannya, kajian yang dikenal 
pasti dominan DENV-1 dan DENV-2 strain dijangka akan berkembang penduduk asli 
Malaysia pada masa akan datang. Penentu antigen yang terlibat telah dikenal pasti. 
Hasil kajian secara langsung menggariskan kesan mutasi ini pada DENV-1 secara 
semula jadi yang baru muncul dan DENV-2 dalam populasi Malaysia dan implikasinya 
terhadap penderitaan denggi dan reka bentuk vaksin. 
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INTRODUCTION 
Dengue virus (DENV) infection is an example of infectious disease that presents 
antigenically variable strains that are capable of evading immune response. Mutant 
DENV strains could evolve under selection pressure by altering their antigenic 
determinants to reduce their immunogenicity. Competition between co-circulating 
strains facilitates the selection and adaptation of the fittest genotype, leading to the rise 
of new genotype from the pre-existing genotypes. The new strains become established; 
transmit its lineage to the host population thereby causing an epidemic outbreak. 
Antigenic evolution of DENV is seen as a process in which the new virulent strains 
emerge by evading herd immunity in a population. The new strain evolves as a result of 
variation in antigenic proteins due to the response to antibody selection. In DENV, these 
variations comprise of minor or major changes in antigenic proteins, leading to new 
antigenic properties such that antibodies in the population no longer recognize the virus. 
The acquisition of new antigenic properties changes the ability of the existing antibodies 
to neutralize the virus by interfering with antibody binding or receptor binding. 
Consequently, the antibodies produced in response to existing virus have decreased 
effectiveness against the virus strains with new antigenic properties. This leads to 
immune escape and the rise of a new dominant virus strain. Although considerable 
information is available on DENV evolution, however, very little is known on how 
exactly changes in the virus antigenic properties could have contributed to the antigenic 
evolution of DENV in hyper endemic population. 
 
In recurring dengue outbreak, attention has been focused on selective and adaptive 
evolution of DENV. Interest in the area was instigated by evolutionary pattern 
suggesting that much of the lineage turnover is driven by selection on the viral genotype 
(Halstead 2008b). Subsequently, other groups reported that majority of antigenic 
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variations that arise within each host are likely to give rise to diverse viruses able to 
adapt to selective pressures (Twiddy et al. 2003; Twiddy et al. 2002b). Since then, 
genetic changes in DENV which circulated at irregular intervals causing disease in short 
periods were reported (Bennett et al. 2003). Most of these studies have hypothesized 
that an increase in disease severity might be the result of multiple infection of DENV 
having been selected to escape neutralization antibodies (Guzman et al. 2000a). These 
studies collectively look for changes in E that might signify emergence of neutralization 
escape mutants (Rico-Hesse 2003; Rico-Hesse 2010). Over twenty publications on 
genetic evolution of DENV found no changes in E that might signify emergence of 
neutralization escape mutant (Guzman et al. 2000a; Halstead 2008a). However, a clear 
pattern of virus evolution during epidemic outbreaks was observed (Guzman et al. 
2000a; Halstead 2008a; Rodriguez-Roche et al. 2011). These changes require further 
studies and research. 
 
In the last two decades, DENV-1 and DENV-2 are the more persistent genotype causing 
major outbreaks in Malaysia (Abubakar and Shafee 2002; AbuBakar et al. 2002b; Teoh 
et al. 2010). Genetic analysis of E shows that the highly susceptible DENV-1 and 
DENV-2 demonstrates a clear pattern of evolution from being minor strains (strains less 
frequent during an outbreak) to dominant strains (frequent throughout an outbreak) 
(Danlami et al. 2012; Teoh et al. 2012). This suggests that the minor strains may act as a 
springboard for the emergence of dominant strains by acquiring some characteristics of 
the minor strains. Thus, assessing the functional importance of the major variable 
antigenic sites on E of DENV-1 and DENV-2 genotypic strains in Malaysia would 
provide new insights into their antigenic evolution. In this study, we investigate the 
effects of dominant strains acquiring the characteristics of minor strains in recurring 
dengue outbreaks in Malaysia.  
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1.0 LITERATURE REVIEW 
1.1 DENGUE 
1.1.1 DISEASE 
Dengue fever is caused by the arthropod-borne flavivirus. It is characterized by biphasic 
fever, myalgia or arthralgia, rash, leukopenia and lymphadenopathy (Halstead 1980; 
Halstead 2008b). Dengue haemorrhagic fever (DHF) is a severe, potentially foetal, 
febrile disease caused by DENV characterized by capillary permeability that leads, in 
severe cases, to a dengue shock syndrome (DSS) (De Madrid and Porterfield 1974). 
There are four antigenically distinct members of the dengue subgroup of the genus 
flavivirus. These are named dengue types 1 through 4 (DENV-1, DENV-2, DENV-3 
and DENV-4) (Halstead 1980; Halstead 2008b). 
 
Many genera of subhuman primates are susceptible to infection by DENV. Species 
belonging to Macacus, Pongidae, Certhopicicus, Cercocebus, Papio, Hylobates and 
Pan can be infected by bites of virus-infected mosquitoes or by injection of infectious 
virus preparations (Halstead 2008b; Rudnick 1965). Infection is essentially 
asymptomatic but viremia occurs at levels sufficient to infect mosquitoes (Rudnick 
1966; Wallace et al. 1980). In the early 1980’s, an extensive epizootic outbreak of 
DENV-2 involving subhuman primates was recognized over wide area of West Africa 
(Chungue et al. 1993). During successive outbreaks, DENV-2 strains were recovered 
from humans after being transmitted by mosquitoes that also feed on subhuman 
primates (Diallo et al. 2005; Fernandez et al. 2004; Moncayo et al. 2004). 
 
In humans, primary clinical features of dengue depend on susceptible host. The 
infection in infants and young children may appear as undifferentiated febrile diseases 
associated with maculopapular rash (Burke et al. 1988; Kliks et al. 1988). In children 
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and adults, symptoms like high fever, headache, myalgia, joint pains, nausea, vomiting 
and rash may be observed. In most cases leucopoenia and thrombocytopenia are also 
visible. DHF/DSS are commonly observed in older children experiencing secondary 
dengue infection (Halstead 1970). Dengue symptoms in primary and secondary 
infections are undifferentiated. However, on day three through seven the haemorrhagic 
manifestations could begin to appear. DHF is characterized by the occurrence of high 
fever, hepatomegaly and circulatory collapse (Srichaikul and Nimmannitya 2000; 
Vaughn et al. 2000). Thrombocytopenia with concurrent hemoconcentration, a sign of 
plasma leakage is a common clinical symptom. In some cases, DHF patients may 
deteriorate rapidly leading to shock syndrome (DSS) generally occur after 
defervescence- a fall in temperature between third and seventh day of fever (Burke et al. 
1988).  
 
There is no specific treatment for dengue; hence, management of the disease has always 
been supportive therapy. Patients with high fever may be given antipyretics or 
acetaminophen (Kliks et al. 1988). Patients that show signs of plasma loss would 
require intravenous fluid therapy for fluid replacement. Transfusion is only required 
when there is substantial bleeding accompanied by hematemesis and melena (Kliks et 
al. 1988). Most patients with DF, DHF or DSS usually have a good prognosis. The 
foetal cases are usually because of failure of recognizing and managing occult internal 
bleeding with prolonged shock (Boonpucknavig et al. 1979; Kliks et al. 1988). 
 
1.1.2 TRANSMISSION 
To date, mosquito-borne DENV have two discrete transmission cycles: a sylvatic cycle 
between non-human primates and sylvatic Aedes mosquitoes, and an endemic cycle 
between humans and peridomestic Aedes mosquitoes (primarily Ae. aegypti and Ae. 
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albopictus) (Joshi et al. 1996; Rosen 1987). The sylvatic cycle occurs in the jungle 
between the non-human primates and sylvatic mosquitoes (Monath 1994; Uzcategui et 
al. 2001; Wang et al. 2000). The non-primates serve as the host and reservoir. The 
sylvatic cycle involve several Aedes mosquito species found in the forest of most 
tropical countries in Africa and Malaysia in the Southeast Asia (Cardosa et al. 2009; 
Monath 1994; Vasilakis et al. 2011).  The human endemic cycle is associated with the 
peridomestic mosquitoes Ae. aegypti and Ae. albopictus and a susceptible human host 
(Figure 1.1). In the human endemic cycle, human individual serves as the reservoir and 
the amplifying host. The mosquito dwells in human habitats and this contribute to 
transmission into multiple hosts. The viremic period in a dengue-infected person is 
usually two to seven days (Chaturvedi et al. 1992; Kalayanarooj et al. 1997; Luz et al. 
2011; Rico-Hesse 2010). The incubation period in an infected mosquito usually lasts for 
three to ten days, during which the virus continues to replicate in the mosquitoes midgut 
through body tissues and then into the salivary gland (Cox et al. 2011). The virus can be 
transmitted to a susceptible host through its saliva. Once the virus is inside the human 
body, it migrates to other organs such as liver and spleen. The virus replicates in these 
organs before it is released into the bloodstream. Dengue fever symptoms appear after 
an incubation period of 3 to 10 days, and the mosquito remains infectious for days or a 
week (Gubler 1998b; Gubler 2002; Gubler et al. 1986; Smith 1956). 
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Figure 1.1. Modified diagram showing the dengue transmission cycle (Gubler 1998a). 
 
In exceptional cases, dengue can be transmitted during blood transfusions from infected 
donors onto a healthy individual (Khin and Than 1983; Perret et al. 2005). There are 
also reports suggesting infected pregnant mother transmitting the virus to her neonate 
(vertical transmission) (Basurko et al. 2009; Phongsamart et al. 2008). In many dengue 
endemic areas, dengue occurs every year usually when there is optimal condition and 
availability of breeding sites for the Aedes mosquito (Monath 1994; Wang et al. 2000). 
These areas are at risk of an epidemic, especially when a large number of vector 
mosquitos’ presence coincides with a large number of people with no prior immunity to 
the circulating DENV serotypes. The lack of DENV transmission in some endemic 
areas could be attributed to sporadic contact between vector and the host (Halstead et al. 
2001; Lambrechts et al. 2010; Lin et al. 2004; Luz et al. 2011). 
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1.1.3 EPIDEMIOLOGY AND HISTORY   
Dengue is prevalent in over 125 countries in Asia, Pacific, the Americas, Africa, and the 
Caribbean (Guzman et al. 2000a; Monath 1994). An estimated 2.5 billion people, 35% 
of the world’s populace, live in areas that are at a greater risk of dengue transmission, 
(Figure 1.2). There is an estimated 100 million cases of DF annually, with 500,000 DHF 
cases and 22,000 deaths, commonly within school-going children (Guzman et al. 2002; 
Simasathien et al. 2008). 
 
 
Figure 1.2. Global distribution of dengue virus (WHO 2010). 
 
The first dengue-like infection was reported in China during the Chin Dynasty 
(McSherry 1982; Siler 1926). Dengue-like infections were also reported in French West 
Indies in 1635 and Panama in 1699 (McSherry 1982). Epidemics of dengue infections 
were reported in 1779 in Jakarta and Cairo (Siler 1926). Dengue was first reported in 
Malaysia over a century ago(Skae 1902). In Southeast Asia, the first epidemic outbreak 
was reported in Manila Philippines in 1954 just after the Second World War. This could 
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be due to influx of traders, tourists and immigrants (Halstead 2008b).   Historically this 
was followed by record of dengue outbreaks in Malaysia (Rudnick 1965; Smith 1957). 
By early 1960s, dengue has become well entrenched in Malaysia (Abubakar and Shafee 
2002). The first confirmed case of DHF was reported in 1962 (Rudnick 1965)and it 
coincided with similar reports in neighbouring countries; the Philippines in 1956 
(Hammon 1966), Thailand 1958 (Rudnick 1966) and Singapore 1960 (Rudnick 1966; 
Wallace et al. 1980) in that order. DENV-1 was first isolated in Malaysia (Abubakar 
and Shafee 2002; Smith 1957). Since then other serotypes of DENV were isolated and 
all have caused DF/DHF outbreaks in Malaysia (Abubakar and Shafee 2002; AbuBakar 
et al. 2002b). Each outbreak is usually associated with at least one dominant serotype of 
DENV-1, DENV-2 or DENV-3. Outbreaks involving DENV-4 are rare.  The last 
DENV-4 major outbreak was in the 1960’s (Abubakar and Shafee 2002; AbuBakar et 
al. 2002b). 
 
1.1.4 PATHOGENESIS OF DENGUE INFECTION 
There are two independent mechanisms, which have been hypothesized to describe the 
disease progression in dengue infection.  The first mechanism is the antibody dependant 
enhancement. There is evidence suggesting that individuals with pre-existing antibody 
from late infection with one of the DENV serotypes are predisposed to more severe 
dengue if subsequently infected by a different DENV serotype (Falconar 2008; Gubler 
1998a; Halstead and O'Rourke 1977; McBride and Bielefeldt-Ohmann 2000; 
Stephenson 2005; Whitehorn and Simmons 2011). This implies that there is an 
association between DENV-antibody complexes with secondary heterotypic DENV 
infection. This occurs when there is an increase in the virus uptake during entry into the 
FcγR (fragment, crystallisable gamma receptor) receptor-bearing cells through the Fc 
(fragment, crystallisable) portion of a non-neutralizing antibody. This mechanism in 
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turn increases disease severity and viral load in dengue patients (Halstead 1970; 
Halstead 2003). Consequently, the virus incubation period is reduced. Host 
mononuclear phagocytes are destroyed and lead to the release of vascular permeability 
factors and complement activating factors. The increase of viral load because of 
enhanced entry of viruses would result in sufficient formation of virus- immunoglobulin 
gamma complexes that would increase activation of the complement pathway resulting 
in increased complement consumption. Complement (C) reduction would release C3a 
and C5a anaphylatoxins. This promotes vascular permeability that may lead to 
DHF/DSS (Cardosa 2000; Halstead et al. 2005; Halstead and O'Rourke 1977; McBride 
and Bielefeldt-Ohmann 2000; Rothman 2010; Whitehorn and Simmons 2011). The 
enhancement of DENV infection was observed in monkeys infected with DENV-1 and 
DENV-3 in vivo and subsequently boosted with DENV-2. The monkeys developed high 
levels of viremia when compared with the non-immune monkeys given the same dose 
of DENV-2 (Halstead 1979; Halstead et al. 1973). Similar observations were made 
when monkeys infected with DENV-1 cord blood were boosted with DENV-2 
(Halstead 1979). 
 
Alternatively, evidence of severe dengue in individuals with no detectable anti-dengue 
antibodies has been reported to correlate with the more virulent strains of dengue   
(Guzman et al. 2002; Guzman and Vazquez 2010; Halstead et al. 1983). This suggested 
that severe dengue could be associated with DENV virulence. This argument is 
reinforced with cases of severe DENV-2 DHF epidemics in Cuba in 1981 following 
DENV-1 epidemic in 1977 (Guzman and Kouri 2003; Guzman et al. 2000b). Similar 
observations were made with the introduction of Asian DENV-3 into the Americas 
(Gubler and Clark 1995).The lack of severe cases of dengue virus in endemic regions 
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with prior existing antibody to another dengue virus serotypes could be due to also 
population difference (Watts et al. 1999).  
 
In addition, thymus (T) lymphocytes have also been implicated in contributing to 
dengue severity. Serotype-cross-reactive memory T-cells, tend to reactivate during a 
secondary infection. An abnormal T-cell activation cascades and apoptosis will occur 
(the original antigenic sin) (Halstead et al. 1983; Kuno et al. 1993; Midgley et al. 2011b; 
Rothman 2011). This abnormal response increases the T-cell population of the lower 
avidity memory T-cells during secondary DENV infections. The response favours the 
former over the naïve T-cell following a new infection (Chaturvedi et al. 2000; Halstead 
and O'Rourke 1977; Midgley et al. 2011a; Rothman 2010). 
 
Genome structural differences between the virus strains also correlate with severe 
dengue infections and pathogenesis. Leitmeyer (1999) identified that the primary 
determinants of DHF reside in (i) amino acid 390 of the E, which purportedly alters 
virion binding to host cells; (ii) in the downstream loop (nucleotides 68 to 80) of the 5′ 
non translated region, which may be involved in translation initiation; and (iii) in the 
upstream 300 nucleotides of the 3′ non translated region, which may regulate viral 
replication via the formation of replicative intermediates (Leitmeyer et al. 1999; Rico-
Hesse 2003).  Effect of these mutations using DENV-2 was evaluated in human primary 
cell lines. They account for cell tropism and virulence in primary human cells 
(Armstrong and Rico-Hesse 2003; Cologna and Rico-Hesse 2003; Rico-Hesse 2003). 
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1.2 DENGUE VIRUS 
1.2.1 TAXONOMY OF FLAVIVIRUSES 
Flavivirus is from the Latin word flavus-meaning yellow- characterized by the jaundice 
caused by Yellow Fever virus (YFV). The genus flavivirus includes two other genera 
namely, Pestivirus and Hepacivirus, primarily transmitted by arthropods 
(Mukhopadhyay et al. 2005). The flaviviridae family includes 73 viruses divided into 
non-vector transmitted, tick-borne and mosquito-borne Flavivirus(Mackenzie et al. 
2004). DENV belongs to the mosquito-borne Flavivirus group. A number of other 
Flavivirus comprise the Yellow Fever virus from which the group derives its name. And 
there is the Japanese encephalitis virus (JE). The tick-borne encephalitis virus (TBEV) 
and West Nile virus (WNV) are also members of genus Flaviviridae. Majority of the 
Flaviviridae family are human pathogens and cause serious outbreak and epidemics 
around the world (Calisher and Gould 2003; Mackenzie et al. 2004; Mukhopadhyay et 
al. 2005). 
 
1.2.2 CLASSIFICATION OF DENGUE FEVER VIRUS 
Flaviviruses have different virion morphology and genome organization. The 
serological relationship, however, can been determined by (1) antibodies (monoclonal 
or polyclonal); (2) by using neutralization tests and hemagglutination-inhibition (HAI); 
and (3) identification based on complement-fixation activity associated with the non-
structural 1 protein. Neutralization tests have been used to identify Flaviviruses 
serological subgroups. One of these serogroup is the dengue serogroup (Halstead 1980; 
Halstead et al. 1973).  
 
Nucleotide sequencing of regions of the E, NS3 or NS5 of most flaviviruses has resulted 
in more detailed relationships than was possible by serological studies. The current 
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classification of the genus flavivirus is mainly based on genetic groupings (Figure 1.3 
(Churdboonchart et al. 1991; Churdboonchart et al. 1990). Although, scientists have 
discovered a new type of the virus- DENV-5, that causes a centuries-old epidemic, 
dengue (Normile 2013). flavivirus classification identified four different dengue 
serotypes that tend to relate to the geographic origin of the virus strain, each exists as a 
single serotype (Halstead 2008b). 
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Figure 1.3. Phylogenetic tree of DENV strains from all 4 serotypes. The phylogeny 
was inferred using Bayesian analysis (one million reiterations) and all horizontal 
branches are scaled according to the number of substitutions per site. Bayesian 
probability values are shown for key nodes. Virus strains are coded by abbreviated 
country of collection/strain name/year of collection. (Weaver and Vasilakis 2009). 
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1.2.3 STRUCTURE OF THE DENGUE VIRION 
Flavivirus particles are spherical in shape, with a lipid envelope; the particles are 
approximately 50 nm in diameter. The lipid envelope is derived from host cell 
membranes and constitutes 15–20% of the total weight of the virus particle. 
Carbohydrates represent 9–10% of the weight of virus particles and are found as 
glycolipids and glycoproteins (Halstead 2008b; Kuhn et al. 2002). DENV genome is a 
positive sense single-stranded RNA genome. A single continuous open reading frame, 
representing 95% of the genome translated to a single large polyprotein (around 10 kb 
in length) (Gubler 1998b). The ORF is flanked by the 5` and 3`un-translated region 
(UTR). The genome is packaged by the host-capsid protein in a host-derived lipid 
bilayer. This produces three structural proteins, the capsid (C), premembrane (prM/M) 
and Envelope (E), which form the virus particles. The seven non-structural (NS) 
proteins consist of NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 that are essential 
for virus replication (Figure 1.4) (Kuhn et al. 2002; Markoff 1989). The DENV-1, 
DENV-2, DENV-3 and DENV-4 open reading frames are estimated to contained 
10,188, 10,173, 10,170, and 10,158 nucleotides in length, which encode polyprotein 
precursors of 3396, 3391, 3390 and 3386 amino acids, respectively (Blok 1985; Kuhn et 
al. 2002; Weaver and Vasilakis 2009). 
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Figure 1.4. Schematic depicting the DENV genome  
 
1.2.3.1 The capsid protein (C) is the smallest, (9-12 kDa) consisting of 112 to 127 
amino acids. The C is a highly positive-charged residue. It is associated with the 
negatively charged viral RNA genome during virus replication to make the 
nucleocapsid core (Trent 1977; Yu et al. 2008).  
 
1.2.3.2 The premembrane/membrane protein (prM/M) is the second smallest protein of 
27-31 kDa. The protein exists in two forms; prM, (precursor form associated with the 
intracellular immature virion) and M (found in extracellular mature virion). Cleavage of 
prM to M by a cell encoded furin-like protease at the cleavage maturation motif is an 
essential and terminal event in the virus (Cardosa et al. 2002; Markoff 1989). The 
process changes the virus surface structure and results in an increase of virus fusogenic 
activity and infectivity. The prM also serves as chaperone protein for E. It protects from 
irreversible conformational damage in the low-pH environment. This occurs during the 
virus maturation process in the trans-Golgi network (Kuhn et al. 2002; Yu et al. 2008).  
 
1.2.3.3 Envelope protein (E) is the largest DENV structural protein. The protein is 
approximately 55 to 60 kDa in size. It consists of 494 to 501 amino acids. The two 
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glycosylation sites at E67 and E155 (Bryant et al. 2007; Johnson et al. 1994; Mondotte 
et al. 2007) makes up the principal component of the virus surface (Modis et al. 2005). 
E exists as a dimer (Modis et al. 2004; Modis et al. 2005). The two monomers consist of 
three domains, a main structure (EDI), flanked by the dimerization domain (EDII) and 
an immunoglobulin (Ig)-like domain (EDIII). EDII include the conserved fusion loop at 
the distal end of EDI and EDIII, which is embedded within the target membrane. 
Rearrangements of domains I and II with respect to domain III suggest that a folding 
back of the E trimer occurs which would bring the virion and target membranes into 
close proximity, leading to lipid mixing and membrane fusion (Modis et al. 2004). 
Domain III is thought to contain the putative receptor binding sites (Beasley 2005). The 
E plays critical roles in fusion and interaction of the DENV with cellular receptors 
(Chen et al. 1996). It also serves as target for host humoral response, resulting in 
neutralization of the virus (Kuhn et al. 2002; Modis et al. 2004; Rey 2003; Weaver and 
Vasilakis 2009). 
 
1.2.3.4 NS1 is the most extensively studied DENV protein. This antigenic protein is 42 
to 50 kDa, is glycosylated, and exists as a dimer in its basic form in the intracellular and 
extracellular fluids of infected cells (Abubakar et al. 2002a; Mason et al. 1990). The 
NS1 plays a role in virus maturation. The immature E in the endoplasmic reticulum 
lumen is associated with the synthesis of the negative strand in the RNA replication 
cycle (Jacobs et al. 2000; Somnuke et al. 2011; Winkler et al. 1989). 
 
1.2.3.5 The NS2A is 20 to 22 kDa protein. It is necessary for the proteolysis of the C 
terminus of NS1 and coordinating RNA packaging and replication (Weaver and 
Vasilakis 2009). A possibility of interferon antagonizing is also reported (Calvert et al. 
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2006). This hydrophobic protein is suggested to play a role in mature viral assembly 
(Blaney et al. 2003; Kuhn et al. 2002). 
 
1.2.3.6 NS2B is a14.5-kDa protein. It is a membrane-associated protein, which 
functions with NS3 to serve as cofactor in the structural formation of DENV serine 
protease in NS3 (Leung et al. 2001; Othman et al. 2007; Weaver and Vasilakis 2009) 
and receptor binding (Abubakar et al. 2002a). Recently the protein was reported to play 
a significant role in mediating the activation of NS3 proteases (Weaver and Vasilakis 
2009; Zuo et al. 2009). 
 
1.2.3.7 NS3 is believed to play distinct roles in DENV replication (Falgout et al. 1991). 
The NS3 is a 70-kDa multifunctional protein, which served as both a serine protease 
and helicase together with NS2B. It cleaves the dibasic sites of the viral polyprotein 
during post-translational processing (Jones et al. 2005; Li et al. 1999; Luo et al. 2008). 
 
1.2.3.8 NS4A and NS4B are small hydrophobic proteins of 16 kDa and 27 kDa, 
respectively. The proteins function as RNA replication complex cofactors in the virus 
replication (Cahour et al. 1992). The protein preserved replication efficiency in two 
hosts, human and mosquitoes (Hanley et al. 2003). Mutation at amino acid residue7129 
decreases replication in mosquito cells, and increases replication in simian cell lines 
(Cahour et al. 1992; Hanley et al. 2003).  NS4B also functions as an interferon 
signalling inhibitor (Jones et al. 2005; Kuhn et al. 2002; Munoz-Jordan et al. 2003).  
 
1.2.3.9 NS5 is the largest non-structural protein of about 104 to 106 kDa (Taylor and 
Best 2011). It is believed to be the putative RNA polymerase (residue 270 – 900), and 
methyltransferase for capping the viral RNA during replication (residue 1 – 269) 
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(Cahour et al. 1992; Kuhn et al. 2002). Most recently, the well-conserved protein is 
reported to function in interlukin-8 induction. The same NS5 domain could also have a 
guanylyltransferase activity (residue 387 – 404) (Kuhn et al. 2002; Medin et al. 2005; 
Polacek et al. 2009; Yap et al. 2010). 
 
1.2.3.10 The un-translated region (UTR) of the genotypes includes approximately 100 
and 400-800 nucleotides of un-translated regions at the 5` and 3` ends of the genome, 
respectively(Kuhn et al. 2002; Zou et al. 2009). The regions include several conserved 
structures that forms stem loop. They play a vital role in viral replication and translation 
(Chiu et al. 2005; Gebhard et al. 2011; Mason et al. 1987; Wei et al. 2009). Mutations 
that alter the structural conformation of the UTR were found to affect virulence and 
cause attenuation (Durbin et al. 2001).  A single nucleotide mutation in the 5`UTR of 
the South East Asian strains of DENV-4 resulted in low replication efficiency in 
mosquito cells (Butrapet et al. 2000). The stems loop at the 3` region play a major role 
in determining the regulation and RNA synthesis in many flaviviruses (Holden et al. 
2006). 
1.3. DENGUE VIRUS E 
Dengue virus E is a “class II” viral fusion protein (Schibli and Weissenhorn 2004), 
which initiates attachment of the virus to host cell receptors (Modis et al. 2004; Modis 
et al. 2005). E also mediates fusion with host cell membranes, hemagglutinates 
erythrocytes and stimulates humoral and cell-mediated immune responses. In neutral pH 
environment, E lies parallel to the surface of the viral membrane as dimeric or trimeric 
units. Each monomeric unit anchored to the viral membrane by a carboxyl terminal 
trans membrane region (Modis et al. 2004).  
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1.3.1 MOLECULAR STRUCTURE OF E 
The three dimensional structure of E ectodomain has been resolved at 2 Armstrong (Å) 
(Kuhn et al. 2002; Modis et al. 2005). But it is composed of amino acid residue 1-395 
only. The ectodomain, which is the soluble fragment, is anchored in to the membrane 
through transmembrane domain at residues 451 to 495 (Kuhn et al. 2002; Modis et al. 
2004).The E ectodomain is divided into 3 domains: a main structure (EDI), flanked by 
the dimerization domain (EDII) and an immunoglobulin (Ig)-like domain (EDIII) 
(Figure 1.5). A stem region, residues 396-450, links DENV ectodomain and 
transmembrane domain together. The E forms homodimers with an average dimension 
of approximately 150Å x 55 Å x 30 Å. This dimer is oriented similar to the viral 
membrane and smoothly curled. Infectious virions contain 90 E dimers (180 E 
monomers) covering the entire viral surface and forming a smooth shell (Zhang et al. 
2003). Conservation of cysteine residues and similar hydrophobic profiles suggest a 
common folded structure of the E for all flaviviruses (Howard 2006; Modis et al. 2004; 
Roehrig 2003).  
 
1.3.1.1 EDI of DENV contains 120 amino acids (1-51, 137-189, 285-302)(Mandl et al. 
1989). The domain consists of two beta (β) sheets that constitute eight stranded up and 
down β-barrel in a tightly packed discontinuous hydrophobic region. The domain 
contains a unique glycosylation site. Attached to the loop on the external surface of the 
protein are two disulphide bridges joining the cysteine residues at 3-30 and 186-290 
(Allison et al. 2001; Howard 2006; Stiasny et al. 2002) (Figure 1.5).  
 
1.3.1.2 EDII of DENV consists of 178 discontinuous amino acid residues (52-136 and 
190-284). The domain is a finger-like structure. It consists of antiparallel β-sheets of 
five strands packed within two alpha (α) helices. Sandwiched between the structures are 
20 
 
three stranded β-sheets and one beta hairpin (Allison et al. 2001; Modis et al. 2004; 
Stiasny et al. 2002). Disulphide bridges link the three-β sheets together that stabilizes 
the tightly folded cd loop structure (98-111 amino acids)(Allison et al. 2001). The 
fusion peptide in the cd loop has been reported to be the primary neutralization site and 
the hemaagglutinin site of the virus (Stiasny et al. 2002). Mutation on domain II is 
reported to affect fusion activity essential for the attachment of soluble E to target 
membranes (Allison et al. 2001) (Figure 1.5). 
 
1.3.1.3 EDIII consists of continuous amino acid residues from 303 – 395. EDIII is an 
immunoglobulin like protein withinβ-barrel structure that constitutes two β-sheets. One 
of the β-sheets is in contact with the cd loop and adjacent to domain I, while the second 
sheet forms the outer lateral surface of the dimer. EDIII is projected above domain I and 
EDII through a fifteen amino acids hinge residues and disulphide bridges connecting 
domain I and domain II (Mandl et al. 1989). The projection of EDIII above EDI and 
EDII from the viral surface facilitates its attachments to host cell receptors. Antibodies 
that bind to domain three prevent attachment to host cells (Crill and Roehrig 2001; 
Roehrig 2003). The domain contains Arg-Gly-Asp motif that is specific for mosquito 
borne flaviviruses binding (Lee and Lobigs 2002; Munoz et al. 1998). The region has 
been implicated for heparan sulfate, glucosamine-glycan (GAG) recognition (Howard 
2006; Lee et al. 2010) (Figure 1.5). 
 
In addition to the three antigenic domains, the E contains an amphipathic alpha helical 
stem anchor region that represents 20% of E (Allison et al. 2001) (Figure 1.6). The 
membrane stably folded E fragment with the C-terminal transmembrane anchor. The 
53-residue amino acid residues  have been implicated in membrane anchoring and in 
low pH-induced structural changes associated with virus fusion (Allison et al. 2001). 
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The region also plays an important role in intracellular localization of E in DENV-2 
(Stiasny et al. 2002). 
 
 
Figure 1.5. Structure of DENV E in it dimeric form. The three domains of E, EDI is in 
red, EDII is in yellow, and EDIII is in blue (Modis et al. 2004). 
 
1.3.2. ANTIGENIC STRUCTURE OF DENGUE VIRUS 
The E of flavivirus encodes for important immunogenic properties of the viruses  
(Roehrig 2003). The protein initiate infection through cell binding and these trigger the 
immune response against the proteins. These immunogenic properties mediate virus cell 
membrane fusion (Modis et al. 2004). Antigenic and immunogenic properties of DENV 
E have been determined and were reported to be similar with other flavivirus 
(Gromowski and Barrett 2007; Henchal et al. 1985; Roehrig 2003; Roehrig et al. 1990). 
Following characterization of E of the TBEV, using monoclonal antibodies (Klaus et al. 
2011; Matveeva et al. 1995). The functional antigenic determinant of DENV were 
mapped against the E antibodies (Howard 2006). The regions were similar with that of 
TBEV with three antigenic domains A (EDII), B (EDIII) and C (EDI) (Crill and 
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Roehrig 2001; Roehrig et al. 1998). An antibody against domain A recognized peptides 
at amino acids residues 1-400 and 1-120. It is implicated for hemagglutination 
inhibition, blocks virus fusion to host cell receptors and neutralizes virus in vitro 
(Roehrig et al. 1998). Antibodies against domain B recognized peptides at amino acids 
300-400 base pairs, inhibits hemagglutination and neutralization of DENV infection in 
vitro. However, it does not block virus fusion with host cell receptors (Abd-Jamil et al. 
2008; Crill and Roehrig 2001; Gromowski and Barrett 2007; Imrie et al. 2007). 
Antibodies against domain C does not exhibit hemagglutination, fusion or neutralization 
attributes in contrast to domain A and B (Crill and Roehrig 2001; Gromowski and 
Barrett 2007). 
 
The major antigenic determinant on E of DENV induces protective neutralizing 
antibodies (Aaskov et al. 1989; Gromowski and Barrett 2007; Guzman et al. 2010; 
Howard 2006; Lai et al. 2008; Matsui et al. 2009). This protein releases both 
neutralizing and non-neutralizing antibodies during dengue infection. The neutralizing 
antibodies could be type-specific (Gromowski and Barrett 2007; Serafin and Aaskov 
2001) or cross-reactive neutralizing antibodies (Matsui et al. 2010; Matsui et al. 
2009).The specific antibody neutralization sites were mapped to amino acids 35 – 55 
and 352 – 368 on EDI and EDIII (Roehrig et al. 1990). EDII amino acids 60 – 135, 60 – 
205 and EDIII 298 – 397 amino acid residues (Megret et al. 1992) and amino acids 386 
– 397 (Trirawatanapong et al. 1992). The regions that are responsible for direct binding 
of E to cells and antibodies, have been mapped to amino acids 297 – 349 and 380 – 423 
(Wahala et al. 2009). These two regions have been shown to bind to host cells and 
DENV-2 monoclonal antibody fragment with high affinity (Howard 2006; Wahala et al. 
2010; Wahala et al. 2012) (Figure 1.6A).  
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EDIII has been identified as a core antigenic region (Fig. 1.6B).  EDIII plays vital role 
in binding to antigenic determinant in DENV-1 (Matsui et al. 2010; Shrestha et al. 
2010), DENV-2 (Gromowski and Barrett 2007; Gromowski et al. 2008; Gromowski et 
al. 2010) and other flaviviruses (Allison et al. 2001; Mandl et al. 1989; Roehrig 2003). 
The most effective neutralizing epitopes are located at the lateral ridge of the EDIII 301 
-303, 327 – 330 and 381 -382 of the E (Matsui et al. 2010; Wahala et al. 2009). This 
enables accessibility to antibodies. The lateral ridge was reported to contain antigenic 
determinant that recognizes type specific antibodies (Gromowski and Barrett 2007; 
Gromowski et al. 2008). The EDI/EDII inter-phase (49 -52, 136, 184 – 187 and 266 - 
277) was reported to influence mouse monoclonal antibody binding (Lin et al. 2012; 
Wahala et al. 2010). Antigenic determinants (305 - 308) on A strand of the EDIII of E 
recognized sub complex neutralizing antibodies (Gromowski et al. 2008; Wahala et al. 
2010), (Figure 1.6B). These antigenic determinants are the focus for mapping dengue-
neutralizing antibodies. They are potential targets for inducing natural immune 
responses, which are type specific (Abd-Jamil et al. 2008; Lin et al. 2012; Rothman 
2011; Wahala et al. 2010).  
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Figure 1.6. Structure of DENV antigenic regions on soluble E: (A) the image 
highlighted the three beta-barrel domains of flavivirus E: EDI in red, EDII in yellow 
and EDIII in blue. (B), a detailed image of domain III displaying its antigenic sites 
(Wahala et al. 2010). 
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1.3.3 CELLULAR RECEPTORS 
The mechanisms by which DENV enter host cells has not been completely understood. 
However, the initial step in a DENV infection is the attachment of virus to the surface 
of the host cell via cell receptors (Modis et al. 2004). It has been reported that this 
attachment occurs in two stages.  
First, attachment of DENV to the host cell and its concentration at these sites is 
dependent on the presence of auxiliary molecules. Molecules such as sulphate 
polysaccharide chains or GAGs, heparins sulfate (HS) (Chen et al. 1996; Dalrymple and 
Mackow 2011; Mercado-Curiel et al. 2006). Few researchers have shown how the 
dendritic cell-specific ICAM (intercellular adhesion molecule)-grabbing non-integrin 
protein (DC-SIGN) acts as cellular receptors for DENV (Navarro-Sanchez et al. 2003). 
The glucose-regulating protein 78 (GRP78/BiP) (Jindadamrongwech et al. 2004),  the 
cluster of differentiation 14 (CD14) associated molecules and more recently, the heat 
shock proteins (HSP90) and (HSP70) (Reyes-Del Valle et al. 2005) were also been 
reported to act as cellular receptors. Sometimes, the binding occurs on the cell surface 
immunoglobulin receptors because of the existence of antibodies towards the E (Le 
Breton et al. 2011; Rock et al. 2007). 
 
Moreover, it has been revealed that in the case of the DENV the entry route differs 
between mammalian cells and mosquito cells (Humphery-Smith and Vincendeau 1993; 
Mercado-Curiel et al. 2006; Munoz et al. 1998). Flaviviruses are able to infect various 
different cell lines suggesting that various receptors contributed for flavivirus infection 
and that different flaviviruses could use different receptors. The presence of an 
additional co-receptor has been postulated to explain the restricted tropism of 
flaviviruses (Chen et al. 1996; Smith 2012; Thaisomboonsuk et al. 2005).  
26 
 
  
1.3.4 BINDING AFFINITY OF DENGUE VIRUS E TO CELLULAR RECEPTORS 
Biologically functional antigenic domains were identified on the E of flaviviruses using 
monoclonal antibodies directed against it (Howard 2006). They were described using 
peptides representing the regions of the E (Gromowski and Barrett 2007; Gromowski et 
al. 2008). The cellular receptors were also identified, by studying gene sequences of 
selectively modified viral variants (Chua et al. 2006; Henchal et al. 1986; Megret et al. 
1992; Renneson et al. 2011).  Linear epitope were mapped by overlapping peptides 
based on homology analysis and secondary structure prediction (Aaskov et al. 1989; 
Abd-Jamil et al. 2008). Regions recognized by antibodies were also mapped by fusion 
and expression of antigenic protein in bacteria (Mason et al. 1990; Megret et al. 1992; 
Thullier et al. 2001). 
 
Using phage display technologies peptide sequences that mimic epitopes on the E of 
flaviviruses have been identified from infected Vero cells supernatant using anti-dengue 
monoclonal antibody (Cabezas et al. 2008; Cabezas et al. 2009). Competition binding 
studies of monoclonal antibodies on the E has been used to identify relationships 
between different regions competing for antigenic sites (Abd-Jamil et al. 2008; 
Gromowski et al. 2008; Gromowski et al. 2010). Mutant viruses have also been isolated 
invitro in the presence of neutralizing antibodies (Roehrig et al. 1990; Roehrig et al. 
2004). These processes characterize (i) conformationally-dependant functional antigenic 
determinants.(ii) Identify amino acid changes characteristic of particular 
genotype(Puttikhunt et al. 2008). Inhibition of binding of one antibody by another may 
occur because of distant conformational changes caused by the binding of the first 
antibody. It might occur because of steric hindrance if the relevant epitopes are adjacent 
or overlapping (Wiwanitkit 2005).  
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1.3.5 DENGUE VIRUS FUSION WITH HOST CELL MEMBRANE 
The detailed crystal structure of DENV-2 E provides an insight of interaction of fusion 
peptides with targeted cell membrane (Abd-Jamil et al. 2008). The crystallographic 
structures of the pre-fusion and post-fusion trimeric E molecules were hypothesized to 
be the intermediary steps involved in fusion of E of flavivirus with target cell including 
DENV membranes (Modis et al. 2004). Initially, the fusion loops of the three E subunits 
interacted to form an aromatic anchor structure. This occurs through glycan-mediated 
interaction at the top end of the newly formed trimer (Figure 1.7a). This binding occurs 
through EDIII with a relative increase in endosomal uptake. Secondly, the exposed E 
dimers on the virion will dissociate because of decreased pH in the endosomes. These 
expose the fusion loops and enables EDI and EDII to loosen together relatively (Figure 
1.7b). Slackening permits EDII to deflect from the virion and put in its fusion loop into 
the cell membrane. Lateral protrusion of the EDII destroys interaction between the 
virion and the outer surface. This allows for the reorganization of E monomers, thus 
results in the development of a pre-fusion intermediate in which host cell and viral 
membranes are bridged (Figure 1.7c). Subsequently, these lead to the establishment of 
trimer links spreading through the fusion loops at the tip to EDI at the base (Figure 
1.7d). This is followed by EDIII shifting and rotating to make trimer contacts, 
instigating the C terminal segment of E to fold up the fusion loop and cause the two 
membranes to bend towards each other. A structure called ‘hemi fusion stalks’ is 
formed and serves as an intermediate in the membrane fusion reaction (Figure 1.7e) 
(Modis et al. 2004).  
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Figure 1.7. Diagram showing the proposed fusion mechanism of flaviviruses (Modis et 
al. 2004). 
 
Additional trimer contacts will be created between the stem anchor and EDII projected 
towards the hemi fusion stack and then to the formation of a lipidic fusion pore. The C-
terminus of E is projected towards the fusion peptide, and positioned because of the 
rearrangement of beta strands at the trimer interface folding of EDIII. Finally, the fusion 
loop will be extended along the inter-subunit to create enough contact with EDII (Figure 
1.5f). There are 53 amino acid residues at the stem anchor region connecting the end of 
E with the transmembrane anchor, these residues contribute additional trimer contacts 
with EDII of another subunit (Modis et al. 2004).  
 
1.3.6 ANTIGENIC DETERMINANT ON THE SURFACE OF E 
The antigenic determinants of E are essential in the design of DENV vaccine capable of 
inducing neutralization antibodies against DENV (Lai et al. 2007; Wahala et al. 2010). 
In general, DENV E elicits neutralizing antibodies as well as non-neutralizing 
antibodies. E-specific flavivirus neutralizing antibodies can be either virus-specific or 
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virus cross-reactive. The virus-specific antibodies have the highest neutralizing activity 
in vivo (Mandl et al. 1989; Roehrig 2003). Previous studies identified neutralizing 
antigenic determinant for all the DENV serotypes by generating mutants resistant to 
neutralization for a defined antibody (Gromowski and Barrett 2007; Henchal et al. 
1986). The specificity of E to elicit neutralizing antibodies as well as non-neutralizing 
cross-reactive antibodies shows neutralizing determinants are restricted to certain 
residues on the E (Gromowski and Barrett 2007; Gromowski et al. 2008; Wahala et al. 
2010). Most of the neutralizing epitopes are located on the outer surface of the E and are 
thus accessible to antibodies (Gromowski and Barrett 2007; Gromowski et al. 2008; 
Gromowski et al. 2010; Wahala et al. 2010; Wahala et al. 2009). Table 1.1 and 1.2 
below lists amino acid residues on E reported to affect neutralizing antigenic 
determinants for DENV. 
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Table 1.1: Neutralizing antigenic determinants for dengue virus 
 
 
 
 
 
 
 
 
 
 
 
Virus Antibody Positions ED References 
DENV-1 mAb(M-10) E279 I-II  
(Beasley and Aaskov 
2001; Howard 2006)) 
DENV-1 mAb(M-17) E293 I-III (Beasley and Aaskov 
2001) 
DENV-2 MAb(10F2) E69, E71, 
E112,E124, 
II 
III 
(Lok et al. 2001) 
DENV-2 mAb(6B2) E311 III (Lok et al. 2001) 
DENV-2 mAb(4G2) E169, and E275 I-II (Serafin and Aaskov 
2001) 
DENV-2 mAb(G8D11) E307 III (Lin et al. 1994) 
DENV-2 mAb(62B) E311 III (Lok et al. 2001) 
DENV-2 mAb(3H5) E383,E384,E385 III (Hiramatsu et al. 1996) 
DENV-2 GTX29202, 
GTX77557, 
MDVP-55A, 
MA1-27093, 
20-783-74014 
E310, E312, E332, 
E389, E391 
III (Gromowski et al. 
2008) 
DENV-3 mAb(1H9) E386 III (Howard 2006; Serafin 
and Aaskov 2001) 
DENV-3 mAb(14A4-8) E305, E306, E309, 
E310, E325,E329, 
381, E387 
III (Gromowski and 
Barrett 2007) 
DENV-3 mAb(8A1) 
mAb(1H9) 
E301, E302, E329, 
E380, E386 
III (Wahala et al. 2010) 
DENV-4 mAb(4G2) 
DENV4-4 
E101, E106, 
E107,108 
E211, E215, E217 
II 
 
II 
(Howard 2006; Lin et 
al. 2012) 
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Table 1.2: Neutralizing antigenic determinants identified on multiple dengue virus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Virus Antibody Positions ED References 
DENV-1-2 mAb(Fab 
1A5) 
E106 
E317 
II 
III 
(Goncalvez et al. 2004; 
Howard 2006) 
DENV-1-3 mAb(14A4-8) E306, E308, E381, 
E387 
III (Howard 2006; Wahala 
et al. 2010) 
All DENV mAb(85A) 
mAb(2C1) 
 III (Howard 2006; Wahala 
et al. 2010) 
All DENV FL0231 
&FL0232 (all 
DENV), 
FL0251&DA6
7(DENV-1), 
E83, E86, E300, 
E303, E307, E3310, 
E329, E383, E389, 
E391, 
II  
III 
 
(Howard 2006; Lin et 
al. 2012) 
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1.4 IMMUNE RESPONSE TO DENGUE VIRUS 
1.4.1. INNATE AND ADAPTIVE IMMUNE RESPONSE TO DENGUE VIRUS 
The humoral and cell-mediated immune response induced by DENV infection plays a 
major role in in vivo DENV infection in humans (Halstead 1980; Halstead and 
O'Rourke 1977). During DENV infection in vitro, fibroblasts and monocytes induce the 
production of interferon α andβ, respectively. Consequently, an elevated serum level of 
interferon α is detected (Rodriguez-Madoz et al. 2010; Sanchez et al. 2006). Interferon 
inhibits viral infection in monocytes. These cells are susceptible to lyses by the natural 
killer cells. In comparative studies between DF/DHF and in DSS patients, low level of 
undetectable type 1 interferon signalling genes were observed when antiviral function of 
interferon is blocked (Diamond et al. 2000; Gil et al. 2009; Gubler 1998a; Gubler 2002; 
Kurane et al. 1989; Rolph et al. 2011). 
 
E is the major antigenic protein for inducing neutralizing antibodies (De Rivera et al. 
2008) although neutralizing epitopes have been identified on the M. Genotype cross-
reactive antibodies against E, prM, and NS1are also reported (Lai et al. 2008). DENV 
specific antibody against the E directs complement-mediated lyses and neutralization of 
infection in DENV-infected cells. The processes block virus attachment to cell receptors 
(De Rivera et al. 2008; Gil et al. 2009). The NS1 has been shown to induce antibody-
mediated cellular cytotoxicity, and antibodies against NS1can mediate passive 
protection in mouse and primate models (Henchal et al. 1986; Walker et al. 1988). The 
major target of cell-mediated immunity is NS3 but T-cell epitopes have also been 
identified on E, M, NS1 and NS2A (Halstead 2008b). The prM-specific antibodies bind 
specifically to virions that are not fully matured (Bray and Lai 1991; Valdes et al. 2009; 
Vazquez et al. 2002). Sandwich between the E and prM-specific antibodies is the NS1 
specific antibodies that neither bind to the virion nor is adept at neutralization of virus 
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infection. The NS1 specific antibodies are capable of directing complement-mediated 
lyses of infected cells (Liu et al. 2006; Mellado-Sanchez et al. 2005; Mellado-Sanchez 
et al. 2010; Sierra et al. 2002; Williams et al. 2009). 
 
1.4.2. ANTIBODY 
Antibodies are soluble glycoproteins whose function is identifying and elimination of 
immunogenic substances. They represent one of the main effectors of the humoral 
immunity. They composed of two basic structures, heavy chains and two light chains. 
Grouped into five different classes—IgA, IgD, IgE, IgG, and IgM. They are 
differentiated by the amino acid sequence of one of their basic structures, the heavy 
chain. The IgG, IgA, and IgM are normally induced after viral infection (Rabel et al. 
2012; Waldman et al. 1967). They could be monoclonal or polyclonal and their function 
is based on a specific and physical interaction with the antigen.  
1.4.2.1 Monoclonal antibodies: mAb, these are antibodies made by identical immune 
cells, clones from an exclusive parent cells. They are mono specific antibodies because 
of their ability to bind specifically to a given epitope. The monoclonal antibodies are 
generally produced in vitro using human mouse hybrid cells described by Schwaber in 
1973 (Howard 2006; Schwaber and Cohen 1973; Serafin and Aaskov 2001). 
 
1.4.2.2 Polyclonal antibodies (pAb), the polyclonal serum antibodies are antiserum 
derived from multiple bone marrow cells (B-cells) against specific antigens. These 
antibodies are immunoglobulin molecules capable of identifying and neutralizing 
different epitopes or antigenic determinants. Polyclonal antibodies are generally derived 
from susceptible animals immunized with antigen. The antigens stimulated the 
production of IgG immunoglobulin by B-lymphocytes for specificity against the 
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antigen. General objectives of polyclonal antibodies are basically for experimentation 
and diagnostics (Calisher et al. 1989; Lin et al. 2012; Schwaber and Cohen 1973). 
 
1.4.3 MECHANISM OF NEUTRALIZING ANTIBODIES IN VIRAL INFECTION 
Neutralizing antibodies are essential component in preventing microbial and viral 
infections. For antibody neutralization of virus to occur in vivo, a certain threshold level 
of antibodies is required. A primary antibody response occurs with first exposure to 
the virus. Initially IgM antibody manifests first, then, IgA on mucosal surfaces followed 
by the IgG in the serum. During early stages of dengue infection, the neutralizing 
antibodies produced at this stage could obstruct the virion binding to receptors, block 
uptake into cells and cause aggregation of virus particles. This strategy is adopted in 
response to many enveloped viruses whereby the antiviral antibodies and serum 
complement disrupt membranes through lyses. The non-neutralizing antibodies induced 
at this stage of infection also attach distinctively to virus particles, without significant 
effect. They may enhance infectivity because these antibodies can interact with cell 
receptors on macrophages (Halstead 2003; Halstead and O'Rourke 1977; Wahala et al. 
2010).  
In secondary dengue infection the neutralizing antibody response is more rapid than in 
the primary response. Because the cross-reactive but sub-neutralizing antibodies elicited 
during first infection binds to the second DENV and enhanced the secondary infection. 
This phenomenon is referred to as antibody dependant enhancement (ADE). During 
secondary dengue infection, higher cellular intake of the unneutralized infectious virus 
into the monocytes occurs rather than being eliminated (Halstead et al. 1983). ADE is of 
great concern in natural dengue infection. In vitro studies of sera from infants who 
develop DHF demonstrated occurrence of ADE than sera from infant who develop DF 
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(Guy et al. 2004; Guzman and Vazquez 2010; Kliks et al. 1989). Babies with residual 
maternal DENV specific antibodies were demonstrated to be more susceptible to DHF 
or DSS following primary infection (Guzman and Vazquez 2010; Halstead 2003; Kliks 
et al. 1989).  
In cell-mediated immunity, the CD4
+
 and CD8
+
 T-cells mediate T-lymphocyte response 
to DENV infection (Yauch et al. 2010). The cell-mediated response consists of 
serotype-specific and serotype-cross-reactive responses (Beaumier and Rothman 2009). 
DENV-specific T-lymphocytes response produces cytokines capable of initiating the 
removing of DENV. Interferon gamma (γ) and tumour necrosis factor and lymphotoxin 
inhibit DENV infection of monocytes (Beaumier et al. 2008; Beaumier and Rothman 
2009). Interferon gamma also augments the expression of immunoglobulin receptors, 
which can increase the ADE of infection (Beaumier and Rothman 2009; Friberg et al. 
2011; Kurane et al. 1991; Smith et al. 2004). The serotype cross-reactive T-cells modify 
biologically functional immune response to other DENV serotypes during secondary 
infection (Friberg et al. 2011; Yauch et al. 2009). Specifically, DENV specific CD8
+
 T-
cells were much higher in DHF patients than in DF patients recruited after secondary 
infection (Beaumier et al. 2008; Yauch et al. 2010). The cytokine production will aid 
proliferation of elevated DENV specific T-lymphocytes much earlier in secondary 
dengue infections (Chaturvedi et al. 2000). Similarly, using tetramers of major 
histocompatibility complexes (MHC) peptides have shown elevated DENV-specific 
CD8
+
 T-lymphocytes with high affinity to dengue viral serotypes other than the 
infecting serotype (Testa et al. 2012). A high percentage of the tetramer-positive cells 
were apparently primed to undergo apoptosis. Recent studies reveal that DENV-specific 
CD8
+
T-cellsis not detected by MHC-peptide tetramer staining until after developing 
plasma leakage (Rothman 2011; Yossef et al. 2012). 
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Collectively, effective clearance of a persistent viral infection in our systems requires 
various mechanisms. The most potent and recognized mechanism is the antibody 
neutralization. The infectious agent is recognized and engulfed by the antibody 
(Halstead 2003; Wahala et al. 2009). The binding incapacitates the virus by neutralizing 
it capacity to infect and spread to the targeted cells. This is called neutralization. The 
most potent and effective neutralizing antibodies are of the IgG family (Rodrigo et al. 
2009). These antibodies form complexes with the infecting virus through interaction 
between the Fc portion of IgG antibodies and the Fc receptors on the cell surface for 
phagocytic action. The infecting virus is neutralized destroyed in the process through 
opsonisation. The infected cell is recognized through Fc receptors on the surface of the 
antibody and they are eventually destroyed by the natural killer cells (NK cells). This is 
referred to as antibody-dependent cell-mediated cytotoxicity (ADCC) (Kurane et al. 
1986; Rodrigo et al. 2009). 
 
1.4.4. DENGUE VACCINE 
An impeccable DENV vaccine must be able to induce both effective humoral and cell 
mediated with long-lasting protective immunity against all four DENV serotypes 
(Howard 2006; WHO Initiative for Vaccine Research. and World Health Organization. 
Dept. of Immunization Vaccines and Biologicals. 2008; Wilder-Smith et al. 2010). The 
ideal dengue vaccine must address the likelihood of ADE (Guy et al. 2004). Researchers 
have to date employed various biological approaches in designing and developing 
dengue vaccines. A number of the vaccines have been in various stages of clinical trials 
(Beckett et al. 2011; Bellanti et al. 1966; Capeding et al. 2011; Edelman et al. 2003; Sun 
et al. 2009; Wright et al. 2009). The most extensively trialled vaccines have been the 
live attenuated dengue vaccines (Capeding et al. 2011; Edelman et al. 2003).  The live 
attenuated vaccine was developed in Thailand and licensed by Aventis Pasteur 
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(Kraiselburd 1987; Murrell et al. 2011). The vaccine showed remarkable seroconversion 
rates of 80-90% against the four DENVs following the administering two doses in 
school-age children. Subsequently, another live attenuated dengue vaccine was 
developed by Walter Reed Army Institute of Research (WRAIR) in America and was 
licensed by Glaxo SmithKline(Murrell et al. 2011).  The vaccine had similar 
seroconversion rates in adults comparable to what was observed in earlier study on 
children (Chanthavanich et al. 2006). However, unwarranted immune response resulting 
in incomplete protection and potentiality of enhanced disease severity was subsequently 
observed (Durbin and Whitehead 2010; Murrell et al. 2011; Wilder-Smith et al. 2010).  
 
The immunological basis of the attenuation in dengue vaccine is not clearly understood 
(Wilder-Smith et al. 2010). The potential of the vaccine strain to revert to a virulent 
strain through mutation or recombination is of great concern (Murrell et al. 2011). 
Another DENV vaccine that is currently under development but yet to undergo clinical 
trials is the inactivated whole-virion vaccine (Butrapet et al. 2000; Huang et al. 2000). 
Others have proposed the synthetic peptides, subunit vaccines, vector expression and 
recombinant live vector systems (Edelman et al. 2003; Troyer et al. 2001). The 
infectious cDNA clone derived vaccines and naked DNA are also yet to go on clinical 
trial (Costa et al. 2006; Konishi et al. 2000; Stephenson 2005). These approaches 
however, have proved to improve the immunogenicity and stability of these potential 
vaccines. Stable cDNA clones of flavivirus are now available and can be used to 
engineer an infectious and highly mutated region of the vaccine strain (Butrapet et al. 
2006). These techniques are in addition genetically stable and are seen as more reliable 
in designing novel vaccine for DENV (Butrapet et al. 2006; Robert Putnak et al. 2005; 
Simasathien et al. 2008). An attenuated infectious clone is derived from DENV-4 by 
deleting regions of the 5’ and 3’ UTRs resulted in mutant viruses with low attenuation, 
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immunogenicity and decreased replication in cell culture (Troyer et al. 2001). Similarly 
attenuated DENV serotypes were generated by deleting a 30-nucleotides region of the 
3`UTR of the infectious clones (Durbin and Whitehead 2010; Guzman et al. 2010; 
Wilder-Smith et al. 2010).These clones are still undergoing preclinical trials. For the 
last two decades, significant technological advances have been made but tough 
challenges lies ahead. As reported by Sabin, DENV-neutralizing antibodies are the only 
immune substance shown to prevent dengue infections (Sabin 1952; Sabin and 
Schlesinger 1945). While waiting for the technology to bear fruits, continuous effort in 
innovation and management of dengue patient is needed. A drug to prevent vascular 
leakage with vaccine at hand could save many lives (Avirutnan et al. 2006; Howard 
2006; Trung and Wills 2010). 
 
1.5. DENGUE VIRUS EVOLUTION 
1.5.1 ANTIGENIC EVOLUTION OF DENGUE VIRUS 
Evolving DENV is affected by population size and its modes of transmission. These 
factors are attributes of most RNA viruses. Because of selection and competition 
between strains that carry different beneficial mutations that assures survival of the 
fittest for the best possible strain (Smith et al. 2004; Twiddy et al. 2003). New lineage 
emerges, and it replaces old strains through this processes- emerging/reemerging, and 
thus is capable of evading antibody neutralization (Mackenzie et al. 2004).  
 
High percentage of infectious disease in the world today is credited to the antigenically 
variable pathogens that escape from immunity induced from prior infection or vaccine. 
The emergence and re-emergence of antigenically distinct DENV mutants is credited to 
the ability of the virus to escape antibody neutralization (Chua et al. 2006; Gromowski 
et al. 2010; Guzman et al. 2000a). The effectiveness of antibody response induced for 
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an existing strain to be successful on other emerging strains is highly dependent on the 
difference in their antigenic determinant (Rico-Hesse 2010). Understanding this 
difference is very critical in vaccine strain selection and surveillance. The changing 
pattern of related antigenic determinant gives rise to a large number of variant strains 
with one or more amino acid differences that may function as alternative determinants, 
capable of altering DENV host immunity (Guzman et al. 2000a; Halstead 2003; 
Halstead 2008b; Rico-Hesse 2010).   
 
There is little evidence of selection pressure that leads to antigenic evolution of DENVs 
in nature. However, selection on E resulting in multiple introductions has been reported 
in DENV-2 (Bennett et al. 2003; Twiddy et al. 2002a) and in DENV-3 and DENV-4 
(Twiddy et al. 2002b). Bennett (2010) reported evidence of antigenic evolution because 
selection pressure acting on NS2A of DENV-4 viruses (Bennett et al. 2010; Bennett et 
al. 2003). These strains with altered antigenic determinant can enhance their 
immunogenicity in a variety of ways, generating different antigenic genotypes. The 
different genotype competes in host.  The fittest strains become established and transmit 
it lineage. The new strains introduced to the host population in a short time interval, 
thereby causing an epidemic outbreak (Chen et al. 2008; Guzman et al. 2002; Rico-
Hesse 2010).  
 
Dengue infection is an example of infectious diseases that presents antigenically mutant 
strains that are capable of evading immune response. The virus can evolve under 
selection pressure (Rico-Hesse 2003; Rico-Hesse 2010; Teoh et al. 2010; Twiddy et al. 
2002a). The immune pressure exerted by the virus is related to its ability to infect and 
transmit between mosquito and susceptible host. This process of antigenic evolution can 
be quantified between virus and the strain with prior exposure. The ability of the variant 
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strain to evolve depends on its ability to alter its antigenic determinant for binding 
specificity and attachment to cellular receptors during fusion (Dunham and Holmes 
2007; Lin et al. 2004; Wahala et al. 2010; Wahala et al. 2009). 
 
Recombination within each of the DENV strains has also been observed to contribute to 
antigenic evolution of DENV (AbuBakar et al. 2002b; Worobey et al. 1999). 
Convincing proof of recombination between strains has now been obtained from a 
patient infected with DENV-1 and DENV-2 recombinants (Lai et al. 2008; Pethel et al. 
1992; Worobey et al. 1999) and in DENV4 (AbuBakar et al. 2002b). Prevalent 
intragenotype recombination that leads to antigenic evolution of new strains was 
identified among all four DENV serotypes (AbuBakar et al. 2002b; Craig et al. 2003; 
Tolou et al. 2001; Worobey et al. 1999). 
 
The DENV E is one of the well-studied antigenic proteins because of its role in virus 
evolution (Howard 2006; Lee et al. 2006; Upanan et al. 2008). The relationship between 
neutralization escape and structural function of DENV antigenic protein in 
hyperendemic areas like Malaysia where dominant strains co-circulate with minutes or 
strains is imperative in understanding the pattern of evolution. Changes in the amino 
acid residues are related to antibody neutralization escape (Gromowski et al. 2010; 
Guzman et al. 2000a). Confirming the specificity and effects of these changes in 
endemic areas is vital in preventing future outbreaks. 
 
1.6. PHAGE DISPLAY 
Biological techniques are very powerful tools in molecular research. Phage display 
technology is one of the prevailing techniques commonly used in molecular research 
laboratories to obtain libraries of different biological compounds (Goodyear and 
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Silverman 2008; Smith 1985). Phage display has been effectively used to isolate 
proteins, study protein interactions, and binding affinity. The phage display was first 
developed and adopted by G. Smith in 1985 (Smith 1985). Smith showed the expressing 
protein of interest on the surface of filamentous bacteriophages by fusing the nucleotide 
sequence of the targeted protein into the genome of the phage. The targeted protein 
could be expressed and displayed as a fusion protein as one of the phage coat proteins. 
The system enables selection and screening of biological proteins with specific 
roles(Vithayathil et al. 2011). The most important aspect of the technology is the ability 
to screen quite a number of different proteins by enrichment (Smith 1985; Vithayathil et 
al. 2011). 
 
The phage display system uses bacteriophages, viruses that infect a variety of gram-
negative bacteria using fertility factor (F) pili as receptors. Filamentous phages are a 
group of bacteriophages with a tube-like shape. These phage particles are mainly 
composed of the major phage coat protein, gene 8 (g8p), which are helically arranged. 
Around 2700 copies of g8p form a wild type filamentous phage virion. Three to five 
copies of another phage protein, the gene 3 (g3p) proteins are found at one tip of the 
particle. This protein is responsible for the attachment of phage to the bacterial pili and, 
thus mediates the interaction to the bacteria (Kotz et al. 2004; Smith 1985; Vithayathil 
et al. 2011).  
 
The phage infects bacteria through attaching the phage (g3p) protein to the bacterial F 
pili. This promotes the dissociation of the phage coat proteins on the bacterial surface 
allowing the ssDNA phage genome to enter into the cytoplasm of the bacteria. A 
complementary DNA strand is then synthesized by hijacking replication machinery of 
the host DNA. A replicative form (RF) is formed. This double-stranded DNA serves as 
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a template for the generation of new single-stranded DNA genomes as well as for 
producing phage proteins. The particles assembled in the bacterial membrane and 
phages are released into the extracellular compartment through an extrusion mechanism. 
Filamentous phages are non-lytic bacteriophages; phages are secreted continuously 
without killing the host (Kotz et al. 2004; Vithayathil et al. 2011). To produce and 
isolate recombinant phage displaying recombinant proteins onto the surface of phage, 
DNA sequences of targeted foreign proteins are cloned into the gene encoding the 
minor phage protein coat (g3p or g8p). The DNA sequence must be in frame with the 
minor coat proteins genes. This approach was tiresome and the recombinant phage was 
found to be unstable during assembly and very low yield when transformed into 
bacteria. The problem was addressed by using phagemid vectors to produced 
recombinant clones followed by rescue with a helper phage (Kotz et al. 2004; 
Vithayathil et al. 2011).  
 
Phagemid were generated using phage genome with the plasmid-cloning vector. 
Phagemid are double-stranded DNA hybrid molecules. The phagemid pCANTAB5E 
used in this study is depicted in figure 1.8 (Qi et al. 2012; Weichel et al. 2008). It is 
composed of a plasmid backbone bearing a colicin E1 origin (colE1 ori) enabling the 
phagemid to replicate in the E.coli host cell. It contains M13 origin allowing the 
phagemid to be packaged into recombinant phage particles. Ampicillin resistance gene 
for selection of positive colonies and the β-galactosidase gene (LacZ gene) promoter, 
which allows the inducible expression of the fusion protein “protein of interest-g3p coat 
protein”, were also present. The phagemid expression is inhibited by glucose and 
promoted by isopropyl-beta-D-thiogalactopyranoside (IPTG) and the gene encoding for 
the g3p protein of the M13 phage (Kotz et al. 2004; Qi et al. 2012). Restriction sites 
(RE) are also found for cloning of the protein of interest into the phagemid. An epitope 
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peptide (E-tag) is found on the carboxyl-terminal part of the g3p protein for detection of 
the fusion protein. However, the phagemid lacks all other structural and nonstructural 
proteins, which are required for a phage particle (Kramer et al. 2003). 
 
 
 
 
Figure 1.8. Diagram of the pCANTAB 5E phagemid vector: MCS is the multiple 
cloning sites on the phagemid vector. 
 
Identical wild type phage is used in infecting the phage to complement the structural 
and non-structural protein component of the phage particles. Helper phage M13KO7 or 
VCSM13 is used to infect the phagemid transformed bacteria. This is termed “phage 
rescue” (Gramatikoff et al. 1994; Ontell and Nakada 1980; Vanhercke et al. 2005). The 
helper phage provides the missing protein components needed to package the phagemid 
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into virion progeny. Competition between the helper phage wild type g3p protein and 
the phagemid fusion protein ensures incorporation of the recombinant phagemid 
displaying five copies of encoded fusion protein on g3p(Abd-Jamil et al. 2008).  The 
ability of the rescue recombinant phage in phage display system to limit the expression 
of the wild type g3pmakes it a worthy choice in isolating recombinant proteins against 
specific antigen.  
 
1.6.1 PHAGE DISPLAY OF PROTEINS AND BINDINGS 
One of the greatest potential of filamentous phage is for displaying of recombinant 
proteins as a prototype protein (Lucic et al. 1998; Steiner et al. 2006; Yang et al. 2000). 
The displayed g3p attachment proteins can be modified. Through proper selection, their 
binding properties or affinities may well be improved and manipulated. Researchers 
have used this technology to engineer recombinant proteins to study and evaluate their 
biological properties (Goodyear and Silverman 2008; Kramer et al. 2003). Precisely, 
altered proteins with mutations that increase protein function and enhanced binding 
properties were selected (Chakravarty et al. 2000; Kotz et al. 2004). Intracellular 
proteins were previously displayed as simplified library of complex mutants generated 
using directed mutagenesis (Fuh and Sidhu 2000). Using the technology receptor 
binding variant mutants were produce by altering specific role of each mutant (Abd-
Jamil et al. 2008; Jolly et al. 2001; Yamamoto et al. 2009; Zhang et al. 2009). 
 
Phage display technology can be directed to express random sequence with or without 
prior knowledge of their specific biological functions. This strategy enables 
manipulation of DNA sequences. This is done by expressing and identifying proteins 
with biological activities onto their specific target receptors and producing novel DNA 
binding proteins (Boder et al. 2000; Joyce 1992; Lin et al. 2000).A result of adaptive 
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evolution studies is a basis on which further diversity can be imposed. The genes coding 
for specific proteins as a starting point could be used to create second combinatorial 
library of the selected genes. A few strategies, including site directed mutagenesis could 
be introduced to amplify phage populations and selects for variation on the targeted 
proteins with alter biological properties (Boder et al. 2000; Fong et al. 2005; Lin et al. 
2000). 
 
The availability of random phage libraries has provided a powerful tool for selecting 
peptide sequences that mimic epitopes of infectious agents (Folgori et al. 1994; 
Roccasecca et al. 2001). Constructions of recombinant fusion protein libraries 
mimicking epitopes of DENV proteins using phage display have been reported (Donker 
et al. 2011; Kramer et al. 2003; Vanhercke et al. 2005). Antigen selection that mimics 
mutant immunologically relevant antigenic determinant of DENV was illustrated. B-cell 
epitopes of dengue proteins have been previously identified using mouse monoclonal 
antibodies (Wu et al. 2001; Yao et al. 1995). Using human pAbs against DENV, 
peptides capable of mimicking antigenic determinants of DENV non-structural proteins 
as diagnostic kit/potential antigen for vaccine production were also reported (Amin et 
al. 2009; Chen et al. 2003; Chen et al. 2007; Wu et al. 2003). Juraina (2008) 
investigated the usage of peptides derived from the hypervariable regions of monoclonal 
antibody fragments specific against DENV-2 E as potential inhibitors against the virus 
binding and infection. In the study, linear forms of two complementarily-determining 
regions CDR-L2 and CDR-H3 showed limited activity in inhibiting binding of E to cells 
proteins (Abd-Jamil et al. 2008). Similarly, specific site on DENV E that interacts with 
cells and a neutralizing antibody is developed using serially truncated DENV-2 E 
displayed on M13 phages as recombinant E-g3p fusion proteins (Abd-Jamil et al. 2008). 
This study highlights the power and importance of phage display technology in 
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competitive binding studies. Previously, a recombinant single-chain variable fragment 
(ScFv) of the 3H5-1 monoclonal antibody recognizing the DENV-2 E was developed 
using phage technology with improved binding affinity (Abd-Jamil et al. 2008; Hui 
1998). Collectively, the ability of the recombinant phage particles to bind to intended 
target, and later estimation of binding categorized the technology as a precious approach 
in this study. 
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1.7. RESEARCH OBJECTIVES 
The overall objective of the proposed study is to investigate the antigenic evolution of 
DENV-1 and DENV-2 in Malaysia. To achieve the overall objective the following 
approaches were undertaken.  
 
1. A site directed mutagenesis approach was used to create mutations on DENV-1 and 
DENV-2 E gene cassettes and displayed on phage g3p minor coat protein. The mutated 
phage particles and their corresponding recombinant E were used in competitive 
binding assays to determine the effects of mutations engineered on DENV E gene 
cassettes on the mosquito (C6/36) and mammalian cell lines (Vero).  
 
2. Polyclonal antibodies were generated against the phage particles displaying the 
recombinant E and the recombinant E of the Malaysian DENV-1 and DENV-2 in 
BALB/c mice. Their corresponding polyclonal antibodies were used for binding and 
neutralization escape studies using dominant DENV-1 and DENV-2 isolates. 
 
3. Functional assays were employed to test the immunological properties of the polyclonal 
antibodies and to identify the antigenic site on E of the dominant DENV-1 and DENV-2 
circulating in Malaysia that could play a significant role in neutralization escape and 
selection of dominant strains likely to evolve in the future. This is important for 
determining positions on E likely to influence future antigenic evolution of DENV-1 
and DENV-2 in Malaysian natural population. 
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2.0 MATERIALS AND METHODS 
2.1 CELL AND VIRUS 
2.1.1 CELL CULTURE 
The C6/36 (CRL-1660) (Aedes albopictus) and Vero (CRL-81) (African monkey 
kidney) cells used were purchased from the American Type Culture Collection (ATCC, 
USA). Cells were maintained in Eagle’s Minimal Essential Medium (EMEM) 
supplemented with 10% foetal calf serum (FCS), (Flowlab, Australia), non-essential 
amino acids, 2 mM L-glutamine and 50 IU penicillin/streptomycin (Flowlab, Australia) 
at 28°C and 37°C, respectively.  
 
2.1.2 VIRUS PROPAGATION 
DENV strains used in the study were propagated in C6/36 cell line. The strains and year 
of isolation were listed in the Table 2.1. Briefly, virus stocks were obtained by 
inoculating monolayers of C6/36 cells with MOI of 0.1 at 80% confluency. The virus 
was allowed to adsorb to cells for one hour at room temperature with gentle rocking. 
Following removal of the virus inoculums, the infected cells were cultured in EMEM 
supplemented with 2% FBS, 1 × NEAA and 2 mM L-glutamine until thorough 
cytopathic effect (CPE) was observed. The culture medium, which contained infectious 
virus particles, was saved following centrifugation at 40000 x g and filtered through 
0.22 µm filter (Sartorius, Germany) kept at -70ºC until needed.  
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Table 2.1: DENV-1 and DENV-2 Malaysian strains used in this study 
Isolate Year Genotype Clinical 
status 
GenBank 
Accession no. 
Remarks 
D1.036000 2005 G I a DF Not published Passage 2 
D1.011177* 1997 G I b DF Not published Passage 2 
D1.059280 1987 G I c DF FR666924 Passage 2 
D1.010245 1997 G II a DF Not published Passage 2 
D1.059266 1987/1
997 
G III DF Not published Passage 2 
      
Isolate Year Genotype Clinical 
status 
GenBank 
Accession no. 
Remarks 
D2.1704378 2007 Cosmopolitan DF Not published Passage 2 
D2.1877347 2007 Cosmopolitan DF Not published Passage 2 
D2. 14245* 1997 Cosmopolitan DF Not published Passage 2 
D2. 14281 1997 Cosmopolitan DF Not published Passage 2 
D2. 16041 1998 Asian I DF Not published Passage 2 
 
*Used as backbone to construct E gene cassettes 
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2.1.3 VIRUS TITRATION 
The foci forming assay was adapted to determine DENV infectivity titre using C6/36 
cell lines. The cells, 1.5 × 10
5
 cells/well were seeded in a 24-well plate (Costar, USA). 
Two hundred microliters of ten-fold serial dilution of virus stock in serum-free media 
was added into the wells that were previously seeded with C6/36 cells overnight. The 
plate was incubated at room temperature for 2 hours with gentle rocking for virus 
adsorption. Subsequently, following removal of the mixture, 1ml overlaid medium 
containing 2% FBS and carboxymethylcellulose (CMC) 1.5% (Sigma-Aldrich, USA) 
was added to the wells. The plate was incubated for 3 and 4 days at 28°C in 3% CO2 
atmosphere for DENV-2 and DENV-1 respectively. 
 
2.1.4 FOCI STAINING TECHNIQUES 
Six days post infection, foci of infected cells were visualized using modified 
peroxidase-base foci staining assay (Okuno et al. 1979). The cells were fixed with 200 
µl of 4% paraformaldehyde for 30 minutes at room temperature. Subsequently, cells 
were permeabilized with 200 µl 1 × PBS (8 mM Na2HPO4, 1.5 mM KH2PO4, 0.14 M 
NaCl, 2.7 mM Kill, pH 7.4) (v/v), containing 1% Ideal detergent (Sigma-Aldrich, USA) 
for 15 minutes and washed three times with 1 × PBS  and blocked with 300 µl of 3% 
skim milk for 2 hours at room temperature. The cells were rinsed three times with 1 × 
PBS before the addition of 200 µl of diluted rabbit hyperimmune sera (1:500) in 1% 
skim milk. The plate was incubated for antibody binding for one hour at 37°C followed 
by three times washings with 1 × PBS. Secondary antibody (200 µl), anti-rabbit IgG 
conjugated with horseradish peroxidase enzyme (HRP) in 1% skim milk (1:250) was 
added to the plates. The plate was incubated at 37°C for one hour. The cells were rinsed 
three times with 1 × PBS. Two hundred microliter of HRP substrate (Pierce, USA),  
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(metal-enhanced DAB solution diluted to 1:10 in stable peroxidase buffer) was added 
into each well for detection of focus of infection (foci). Foci were counted and 
expressed as a foci-forming unit per ml. 
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2.2 DESIGN AND CONSTRUCTION OF GENE CASSETTE 
 
 
 
 
 
 
Figure 2.1a: Schematic representation and overview of the methodology 
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Figure 2.1b: Continuation of schematic representation and overview of the methodology 
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2.2.1 FIRST STRAND CDNA SYNTHESIS 
Total viral RNA was extracted from culture supernatant using QiaAamp viral RNA mini 
kit (Qiagen, Germany) following manufacturer`s protocol. Quantitation of RNA was 
determined by measuring OD260 with Nanophotometer (Implen GmbH, Germany). The 
first strand of cDNA was synthesized from viral RNA lysate of a dominant prototype of 
DENV-1 and DENV-2 strains (Table 2.1) with gene-specific reverse primer using 
Superscript III One step RT-PCR kit (Invitrogen, USA) according to manufacturer`s 
protocol. Initially a 12 l reaction volume consisting of reverse primers (250 ng), RNA 
(2 g) and 1 l dNTPs mix (10 mM) was prepared and heated at 65 C for 5 minutes 
and followed by a quick chill on ice.  The 5  First-Strand buffer (4 l), 0.1 M DTT 
(2l) and RNasin Ribonuclease Inhibitor 40 U/l (Promega, USA) was added into the 
mixture.  The mixture was then incubated at 50C for 2 minutes prior to the addition of 
SuperScript III Reverse Transcriptase (200 U).  Subsequently, the cDNA synthesis 
was performed at 55C for 50 minutes and the mixture was heated at 70C for 15 
minutes to inactivate the reaction.  The cDNA was quantitated using Nanophotometer 
and stored at –20C for subsequent use. 
 
2.2.2 POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION OF E 
The gene coding for complete E was amplified using the gene specific primers. The 
primers amplified 1485 bp of the respective DENV-1 and DENV-2 E (Table 2.2). 
Subsequently the gene cassettes were amplified with specific primers containing 
engineered FLAG tag peptide sequence and AlwNI and Bsp120I restriction sites (NEB, 
UK) (Table 2.2), using high fidelity Pfu DNA polymerase (Stratagene, USA).  The 
following PCR conditions and protocol were used for the amplification of full-length E 
of DENV-1 and DENV-2 gene cassettes. 
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2.2.2.1 E GENE CASSETTES REACTION MIXTURE: 
10 x PCR buffer   5.0 µl  
10mM dNTPs mix   1.0 µl 
Forward primer 10 µmol  0.5 µl 
Reverse primer 10 µmol  0.5 µl 
HF DNA polymerase (5U/ul)  0.2 µl 
cDNA template   0.5 µl 
H2O     42.5 µl 
Total     50.0 µl  
 
2.2.2.2 AMPLIFICATION PROGRAM: 
Denaturation    30 seconds  94°C 
Annealing    45 seconds  60°C × 25 cycles 
Extension    1 minute per kb 68°C 
Final extension   15 minutes  68°C 
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Table 2.2: Amplifications primers used to amplified and sequence E gene cassettes 
 
 
 
a
Primers used to amplify full-length E gene 
b
Primers used to amplify E gene cassettes, the engineered restriction site are italic 
While the FLAG tag sequence are shown in bold 
c
Primers on the phagemid vector 
d
Primers used to synthesize cDNA and sequence E gene cassettes 
Primer Primer sequence 5` - 3` Position Polarity Amplicon 
size  
a
DV1EF AT GCG ATG CGT GGG AAT AGG 
CA 
1-22 Sense  
1485 
a,d
DV1ER T TGT CAT CGT CGT CCT TGT AGT 1463-
1485 
Anti-
sense 
a
DV2EF AT GCG TTG CAT AGG AAT ATC 
AA 
1-22 Sense  
1485 
a,d
DV2ER T TGT CAT CGT CGT CCT TGT AGT 1460-
1482 
Anti-
sense 
b
EN1F 
 
GCT AGC AGA GCC TAT GCG ATG 
CGT GGG AAT AGG CA 
1-22 Sense  
1229 
b
ENR1 
 
GGG CCC CCT TGT CAT CGT CGT 
CCT TGT AGT CTG CAC CGT GAC 
TCC TAG GTA 
1463-
1485 
Anti-
sense 
b
EN2F 
 
GCT AGC AGA GCC TAT GCG TTG 
CAT AGG AAT ATC AA 
301-320 Sense  
1532 
b
ENR2 
 
GGG CCC CCT TGT CAT CGT CGT 
CCT TGT AGT CTG CAC CAT AAC 
TCC CAA ATA 
1460-
1482 
Anti-
sense 
c,d
Phage.F CAACGTGAAAAAATTATTATTCGC 2218 Sense  
c
Phage.R GTAAATGAATTTTCTGTATGAGG 2518 Anti-
sense 
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2.2.3 CONSTRUCTION OF GENE CASSETTE 
A purified gene cassettes amplicon from 2.2.2 was digested with AlwN1 and Bsp120I 
restriction enzymes according to the manufacturer`s protocol. The digested fragments 
were inserted into phagemid, pCANTAB5E (Pharmacia, Sweden) corresponding to the 
restriction sites (SfI and NotI) (NEB, UK), to obtain a recombinant phagemid and then 
transformed into XL10-Gold
®
 Ultracompetent E. coli cells (Figure 2.2).  
The gene cassette was designed, constructed and displayed on M13 bacteria phage. The 
E was fused on M13 phages g3p minor coat protein to be displayed as attachment 
protein. E cassettes of DENV-1 (1232bp) and DENV-2 (1532 bp) strains were inserted 
into phagemid vector, pCANTAB5E. The phagemid “pCANTAB5E” vector has an 
origin of replication being the f1 origin for double and single-stranded DNA synthesis 
(plasmid and filamentous phage origins). It also has an ampicillin resistant gene for 
selection of transformed bacteria. The vector also contains a pIII fusion gene for 
expression of g3p-fused proteins. This is under the control of a lacz promoter. A signal 
sequence is fused to the g3p-fused protein to direct secretion of the fused protein. Each 
protein was then expressed with a FLAG-tag peptide sequence at the C-terminal end 
that allowed easy purification using affinity chromatography. The phagemid vector 
allows conversion to infective phage by super infection using phagemid-bearing cells 
containing helper phages.  
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2.2.3.1 LIGATION OF  PCANTAB5E AND E GENE  CASSETTE TEMPLATES 
The following reaction mixture was prepared to ligate the phagemid vector to the E 
gene DNA template. 
DNA Template    5.0 µl 
pCANTAB5E    1.0 µl 
T4 ligase    1.0 µl 
dNTPs mix    1.0 µl 
H2O     4.0 µl 
Total     12.0 µl 
 
The reaction tube was incubated overnight at 16°C. The ligated products were 
transformed into XL10-Gold
®
 Ultracompetent E. coli cells (Stratagene, USA) according 
to the manufacturers’ protocol.  
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Figure 2.3. An overview of the E gene cassettes constructs. DENV-1 and DENV-2 E 
fragments were cloned into pCANTAB5E to obtain the recombinant phagemid.  
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2.2.4 TRANSFORMATION OF RECOMBINANT PHAGEMID INTO XL10-GOLD
® 
Chemical method for transformation of the bacteria was used. The technique is based on 
subjecting the plasmid DNA and chemically-treated ultracompetent bacteria into a mild 
heat shock that creates pores in the cell membrane promoting entry of the plasmid DNA 
into the bacteria. Ten microliter of ligation mixture is mixed with 100 µl of XL10-
Gold
®
 Ultracompetent cells treated with 1.0 µl of β-mercaptoethanol (Stratagene, USA) 
to inactivate surface exposed nucleases and proteins that may adversely affect 
transformation efficiency. The plasmid DNA and the bacteria were heat shocked in a 
heating block at 42°C for 2 minutes and briefly placed on ice. The mixture was then 
transferred into 1 ml Luria Beltane (LB) media (1.0 g of bacto-tryptone, 0.5 g of 
bactoyeast extract, and 0.5 g of NaCl) and incubated for 1 hour at 37°C with gentle 
shaking. Subsequently, 100 µl of the culture were poured on LB agar plates containing 
100 µg per/ml ampicillin, and incubated overnight at 37°C.Positive clones were 
determined by colony PCR and sequencing using BigDye Terminator kit v.3.0 (Applied 
Biosystems, Bedford, MA). Phagemid containing recombinant gene cassettes of DENV-
1 and DENV-2 were extracted and purified using the alkaline lyses of bacterial cells 
(Vogelstein and Gillespie 1979).  
 
2.2.5 COLONY SCREENING 
The proportion of colonies having an insert of the correct size was evaluated by 
amplification of a single colonies using forward primer from phagemid and reverse 
primers from gene insert (Table 2.2). Single colonies from agar plates were selected and 
boiled in 10 µl of distilled water for 5 minutes. The pellets were briefly centrifuged and 
2 µl of the supernatant was transferred directly into an amplification reaction mixture. 
An initial denaturation step of 2 minutes at 94°C was followed by PCR amplification 
cycle.  
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2.2.5.1 COLONY AMPLIFICATION REACTION MIXTURE:    
  
5 x PCR buffer    2.5 µl  
10mM dNTPs mix    0.5 µl 
Forward primer 10pmol/µl   0.25 µl 
Reverse primer 10pmol/µl   0.25 µl 
Taq DNA polymerase (5U/µl)  0.25 µl 
Bacterial colony suspension   2.0 µl 
Distilled H2O     14.25 µl 
Total      20.0 µl  
2.2.5.2 AMPLICON AMPLIFICATION PROGRAM: 
Denaturation    30 seconds  for 94°C 
Annealing    45 seconds  for 60°C × 25 cycles 
Extension    1 minute per kb for 68°C 
Final extension   15 minutes  for 68°C 
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2.2.6 SITE-DIRECTED MUTAGENESIS 
Quick-change Light site-directed mutagenesis Kit (Stratagene, USA) was utilized to 
create single mutation on DENV-1 and DENV-2 E cassettes using primer presented in 
table 2.3 and table 2.4 respectively. The purified phagemid containing gene inserts were 
methylated circular dsDNA plasmids (pCANTAB5E – E) purified from (dam+) E.coli 
strains from 2.2.4. First, mutant strand is synthesized with mutagenic primers by primer 
directed replication of both plasmid strands using Pfu high fidelity DNA polymerase 
with highest fidelity. The double-stranded DNA containing gene insert were extended 
by the mutagenic oligos during temperature cycling to create a mutated phagemid 
containing staggered nicks. The product is treated with Dpn I endonuclease to digest the 
methylated and hemimethylated (5`-Gm
6
ATC-3`) parental DNA template and to select 
the mutated synthesized DNA. The products that contain the mutant and nicked 
phagemid are transformed into competent cells. 
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2.2.7.1 SITE-DIRECTED MUTAGENESIS REACTION MIXTURE: 
10 × reaction buffer    5.0 µl 
10mM dNTPs     1.25 µl 
Primer 1 (125ng)      1.0 µl 
 Primer 2 (125ng)    1.0 µl 
Template dsDNA (50 ng)    1.0 µl 
Quick solution reagent   1.5 µl 
pfu HF DNA polymerase    1.0 µl  
Distilled H2O     38.25ul 
Total      50.0 lµ 
 
2.2.7.2 SITE-DIRECTED MUTAGENESIS CYCLE CONDITION: 
Initial denaturation step   2 minutes  for 95ºC 
Denature DNA strands cycle    30 seconds  for 95ºC × 18 cycles 
Anneal      45 seconds  for 60ºC  
Extension     30 seconds per kb  for 68ºC 
Final extension    5 minutes   for 68ºC 
Finally, DpnI was added to the amplified amplicon and incubated at 37ºC for 5 minutes 
to digest parental DNA template 
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 Table 2.3: Site-directed mutagenesis primers used to create mutations on DENV-1 gene 
cassette 
 
 Primers were designed using the quick-change primer design program on 
Stratagene official website 
https://www.genomics.agilent.com/CollectionSubpage.aspx 
 First alphabet in the name box denotes mutated nucleotide underlined in the 
primer sequence, number denote mutated position and last alphabet denotes 
nucleotide introduced 
 
 
 
 
 
Name Sequence 5` - 3` Polarity 
a481b 5'-gcacagaacatgggacabctgcaactataacaccc-3' sense 
a481b 5'-gggtgttatagttgcagvtgtcccatgttctgtgc-3' antisense 
t511b 5'-ccccaagctcctacgbcggaaatacagctga-3' sense 
t511b 5'-tcagctgtatttccgvcgtaggagcttgggg-3' antisense 
a814b 5'-ggagcgacagaaatccaabcgtctggaacgaca-3' sense 
a814b 5'-tgtcgttccagacgvttggatttctgtcgctcc-3' antisense 
a889b 5'-gacaaactgactttgaaagggbtgtcatatgttatgtgcacag-3' sense 
a889b 5'-ctgtgcacataacatatgacavccctttcaaagtcagtttgtc-3' antisense 
g1093h 5'-atagttactgacaaagaaaaaccahtcaacattgaggcagaacc-3' sense 
g1093h 5'-ggttctgcctcaatgttgadtggtttttctttgtcagtaactat-3' antisense 
a1168b 5'-ggtgaaaaagctttgaaactabgttggttcaagaaaggaagca-3' sense 
a1168b 5'-tgcttcctttcttgaaccaacvtagtttcaaagctttttcacc-3' antisense 
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Table 2.4: Site-directed mutagenesis primers used to create mutations on DENV-2 gene 
cassette 
 
 Primers were designed using the quick-change primer design program on 
Stratagene official website 
               https://www.genomics.agilent.com/CollectionSubpage.aspx 
 First alphabet in the name box denotes mutated nucleotides underlined in the 
primer sequence, number denote mutated position and last alphabet denotes 
nucleotide introduced 
 
 
 
 
Name Name  Sequence 5` - 3` Polarity 
c154r 5'-tgatagaaacagaagccaaaraacctgccactctaagg-3' sense 
c154r 5'-ccttagagtggcaggttytttggcttctgtttctatca-3' antisense 
g211h 5'-tgaccaacacaacaacahattctcgctgcccaaca-3' sense 
g211h 5'-tgttgggcagcgagaatdtgttgttgtgttggtca-3' antisense 
a490b 5'-acaggaaaacatggcaaggaaatcaaabtaacaccacagagtt-3' sense 
a490b 5'-aactctgtggtgttavtttgatttccttgccatgttttcctgt-3' antisense 
a526b 5'-cacagaagcagagttgbcaggctatggcactgt-3' sense 
a526b 5'-acagtgccatagcctgvcaactctgcttctgtg-3' antisense 
a1003b 5'-gggacggttctccatgtaagbtcccttttgagataatg-3' sense 
a1003b 5'-cattatctcaaaagggavcttacatggagaaccgtccc-3' antisense 
a1178b 5'-aattgaagctcaactggtttabgaaaggaagttctatcggc-3' sense 
a1178b 5'-gccgatagaacttcctttcvtaaaccagttgagcttcaatt-3' 
antisense 
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2.2.8 TRANSFORMATION OF PHAGEMID ON TG1 E. COLI 
To obtain mutant of recombinant phagemid, competent TG1 E. coli strain were 
transformed with the mutated synthesized DNA from 2.2.7. Briefly, 10 ml of overnight 
culture of TG1 was transferred into 90 ml of 2×YT (17 g trypticase peptone, 10 g yeast 
extract, 5 g NaCl)/L broth incubated at 37°C until A600 = 0.5. The cells were sedimented 
at 2500  x g for 20 minutes at 4°C. The pellets were gently resuspended in 10 ml of cold 
TSS buffer (LB media containing 10.0 g of polyethylene glycol, 5 ml of Dimethyl 
sulfoxide (DMSO), and 5 ml of 1M MgCl2 in 100 ml) and placed on ice. The mutated 
recombinant phagemid (2 µl) were mixed with 1 ml of competent TG1 cells and kept on 
ice for 1 hour.  The mixture was heat-pulsed for 2 minutes at 42°C, and then placed on 
ice for another 2 minutes. One hundred microliters was transferred into 10 ml of LBG 
medium (LB media containing 20 mM glucose) and incubated for 1 hour at 37°C 
shaking at 200 x g. One microliter of the transformed bacteria were plated out into 
SOBAG plates ((20 g trypticase peptone, 5 g yeast extract, 0.5 g NaCl, 10 ml 1M 
MgCl2, 55.6 ml 2M glucose, 20 mg/ml ampicillin)/900 ml). Phagemid containing 
recombinant gene cassettes of DENV-1 and DENV-2 were extracted and purified using 
the alkaline lyses of bacterial cells and sequenced using BigDye Terminator kit v.3.0. 
The remaining bacteria were used to rescue the recombinant phages. 
 
2.3 RESCUE OF THE RECOMBINANT PHAGES DISPLAYING GENE CASSETTES 
2.3.1 RESCUE OF THE RECOMBINANT PHAGES 
The transformed E. coli TG1 containing the mutant recombinant phagemid from 2.2.8 
were grown in 2×YT-A media (17 g trypticase peptone, 10 g yeast extract, 5 g NaCl)/L, 
100 µg/ml Ampicillin) overnight at 37ºC. The recombinant bacteria in 2×YT-A 
containing 2% glucose (1:10) were cultured at 37ºC until they reached mid-log phase. 
Helper phage, 3×10
10
 pfu/ml of M13KO7 (Invitrogen, USA) was added to the culture. 
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The mixture was incubated for another one-hour at 37ºC, and the phage-infected E. coli 
were sedimented at 1000 x g for 10 minutes and resuspended in 2×YT-AK media 
(2×YT-A, 50 µg/ml Kanamycin). The package phage-infected E. coli TG1 was then 
kept at –70ºC in 20% glycerol until needed.  
 
2.3.2 PURIFICATION OF RECOMBINANT PHAGE PARTICLES 
To prepare purified recombinant phage particles, the infected E.coli from 2.3.1 
sedimented at 1000 x g for 10 minutes and resuspended in 2×YT-AK media and were 
incubated at 37°C overnight. The culture was then re-sedimented at 10000 x g for 10 
minutes. One in a ratio of four (1:4) volume of PEG/NaCl ((200 g Polyethylene glycol 
6000, 146.1 g NaCl)/L) was added to the supernatant. The mixture was kept on ice for 
60 minutes. Precipitated phages were sedimented at 20000 x g for 20 minutes at 4ºC, 
and the supernatant was discarded. The precipitation was repeated three times. The 
phages were subsequently resuspended in sterile TE buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH 8.0). The resulting suspension were filtered through 0.45 µm filters 
(Sartorius, Germany) to remove bacterial cells and stored at 4ºC until needed.  
 
2.3.3 DETERMINATION OF RECOMBINANT PHAGE TITRE 
Purified recombinant phage particles from 2.3.2 were diluted in a series of ten-fold 
dilutions with sterile TE buffer. A small volume from each dilution (10 µl) was mixed 
together with mid-log phase E. coli TG1 (90 µl; A600 = 0.5) and the mixture was 
incubated for 30 minutes at 37 ºC. The mixture of E. coli and serially diluted phage (100 
µl) was then plated out onto 2×YT-AG plates and incubated overnight at 37ºC. The 
number of colonies formed was counted the next day for the determination of the 
recombinant phage titre.  
2.3.4 SUPER INFECTION OF HB2151 WITH RECOMBINANT PHAGE PARTICLES 
69 
 
Because of the amber stop codon between the E-tag sequence and fdg3p protein on the 
phagemid vector, a non-suppressor bacterial strain was used for expression of the 
recombinant E-g3p proteins. Briefly, 100 µl of log phase HB2151 bacteria were 
infected with 10 µl of purified phage precipitated particles and incubated with 
intermittent shaking for 30 minutes at 37°C. To ensure that resulting colonies were true 
nal
r 
(Nalidixic acid resistant) transductions and not carry over from infected TG1 cells, 
E. coli strain HB2151 were culture on SOBAG-N agar plates (SOBAG plates 
containing 100 µg/ml nalidixic acid). Using sterile inoculating loop, the infected 
bacteria were spread onto the SOBAG-N and incubated at 30°C overnight. Positive 
clones from the plate were determined by colony screening and sequencing. Positive 
colonies were sub-cultured into SOBAG-N plates and stored at 4°C for one month until 
used. 
 
2.3.5 EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEIN 
To express soluble recombinant proteins, HB2151 positive clones on SOBAG-N plates 
from 2.3.4 were used. Briefly, 1 ml of overnight culture of a single positive colony from 
the SOBAG-N plate was incubated in 9 ml of 2×YT-AG broth for 1 hour at 30°C. The 
culture was later centrifuged at 1500 x g for 15 minutes. The pellet was resuspended in 
100 ml of 2×YT-A medium supplemented with 0.1mM IPTG and incubated at 30°C for 
5 hours with gentle shaking at 200 rpm. Twenty-five grams of lyses powder (CelLytic 
Express), (Sigma-Aldrich, USA) were added onto the culture directly. The bacterial 
cells were incubated at 37°C for 1 hour with intermittent shaking. 
 
Prior to that,  SigmaPrep Spin Columns (Sigma-Aldrich, USA) were equilibrated at 
room temperature with 50 mM TBS (50 mM Tris-HCl-pH 7.4 and 150 mM NaCl, pH 
8.0). The columns were embedded with 400 µl affinity gel (anti-FLAG™ M2) (Sigma-
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Aldrich, USA). Following incubation, 800 µl of lysed cell solution were added into 
SigmaPrep Spin Columns (Sigma-Aldrich, USA). The columns were incubated for 1 
hour at room temperature. Following that, the columns were washed three times with 50 
mM of 1 × TBS. Protein samples were eluted into a new collection tube containing 10 
µl of 0.5 M Tris-HCl pH 7.4, using 100 µl of 0.1 M glycine, pH 3.0. All centrifugation 
were performed at 8200 x g for one minute at room temperature using microcentrifuge. 
Eluted samples were analysed using Bradford BCA reagent (Pierce, USA) and stored at 
-20°C until needed. The purified protein was incubated with enterokinase (0.02 units 
per 1mg of purified protein) at 22°C for 16hours to produce the digested fusion protein.  
  
2.3.6 SDS-PAGE AND IMMUNOBLOTTING 
Twenty-five microgram per millilitre (25 µg/ml) of purified proteins were mixed with 3 
 SDS sample buffer, boiled at 95C for 5 minutes and resolved in 10% polyacrylamide 
gels.  The proteins were transferred onto nitrocellulose membrane (Millipore, USA) 
using a wet transfer system (Bio-Rad, USA) at 100 Volts for 2 hours.  Membranes were 
blocked with 3% bovine serum albumin (BSA) for 2 hours and then probed with mouse 
anti-FLAG monoclonal antibody for 2 hours followed by washing in 1  TBS buffer for 
10 minutes.  The membrane was further incubated with goat anti-mouse IgG conjugated 
with HRP (Sigma, USA).  The membrane was washed 2 times with 1 × TBS containing 
0.05% Tween (PBS-T) and 1  TBS buffer for 10 minutes each time. The membrane 
was developed using NBT-BCIP (KPL, USA) for five minutes and rinsed with distilled 
H2O for 2 minutes.   
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2.4 BINDING ASSAY 
2.4.1 PREPARATION OF DENGUE VIRUS ANTIGEN IN VERO CELLS 
Vero cells in 75 cm
3
 tissue culture flask at 90% confluence was infected with respective 
DENV shown in Table 2.1 at a MOI = 0.1 for six days at 37°C. The supernatant of the 
infected cells harvested seven days later. DENV particles contained in the supernatants 
were clarified by centrifugation at 10000 x g for 15 minutes at 4°C. Subsequently, one 
volume of sterile PEG/NaCl was added to four volumes of the supernatant and kept on 
ice for one hour. The precipitated virus was then centrifuged at 10000 x g for 30 
minutes at 4°C. The pellets consisting of the PEG-virus complexes were resuspended in 
sterile TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) and centrifuged for 20000 x 
g for 15 minutes at 4°C. Supernatant were filtered through 0.22 µm to ensure only virus 
particles were collected. The virus suspension was aliquoted and stored at -70°C in 20 
% glycerol. The virions were quantified using the Bradford BCA reagent according to 
the manufacturer’s instructions. 
 
2.4.2 OPTIMUM BINDING OF PHAGE PARTICLES ON C6/36 AND VERO CELLS 
C6/36 and Vero cells were harvested at 90% confluence and washed three times in 1 × 
PBS with repeated centrifugation at 800 x g. C6/36 cells and Vero cells at1 × 10
5
 
cells/ml were seeded to occupy all possible non-specific binding sites into 96-well 
plates and fixed with 4% paraformaldehyde for one hour at room temperature. Wild 
type purified recombinant phage particles (2.5 × 10
5
, 2.5 × 10
6
 and 2.5 × 10
7
 cells/ml) 
were added. After an hour of incubation at 37°C, the unbound phages were vigorously 
washed 10 times with 1 × PBS-T and five times with 1 × PBS. Mid-log phase E. coli 
TG1 at A600 = 0.5 was added and the plate was further incubated at 37ºC for 30 minutes. 
The infected E. coli (100 µl) was then plated onto 2×YT-AG plates and incubated 
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overnight at 37ºC. The number of colonies, which represents the number of recombinant 
phages particles bound to the cells proteins, was counted 24 hours later.  
 
2.4.3 BINDING OF VARIANT RECOMBINANT PHAGE PARTICLES 
The binding of recombinant phage particles to DENV susceptible cell lines was 
performed as previously described (Abd-Jamil et al. 2008). Briefly, recombinant phage 
particles (2.5 × 10
6 
cfu/ml) were added to C6/36 or Vero cells fixed in 96-well plates 
using 4% paraformaldehyde. The plates were incubated at 37°C for two hours with 
gentle agitation at every 15 minutes. The unbound phages were removed by extensive 
washing with 1x PBS-T and PBS. The cells were then incubated with TG1 E. coli at 
mid-log phase (A600 = 0.5) at 37ºC for 30 minutes. The E. coli (100 µl) was then plated 
onto 2×YT-AG plates and incubated overnight at 37ºC. The number of colonies, which 
represents the number of recombinant phage bound to the cell surface proteins, was 
counted the day after. 
 
In similar binding study, 2.5 × 10
6
 cfu/ml of the recombinant phage particles were 
precipitated with the pAb described in 2.4.3 using two different dilutions (1:80 and 
1:640) for one hour at 37 °C. Subsequently, the mixture was centrifuged at 40000 x g 
for 15 minutes to pellet the antibody-phage complexes. The supernatant (100 µl) was 
transferred into wells containing the fixed cells. The binding study was performed as 
above (2.4.3). 
 
2.4.4 BINDING OF POLYCLONAL ANTIBODY TO DENGUE VIRION 
The binding of polyclonal antibodies to DENV was determined as previously described 
by (Wong et al. 2007). Briefly, twenty five µg/ml of purified viruses prepared above 
were coated into 96 well plate using 0.5M Na2CO3, pH 9.6, and overnight at 4ºC. 
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Following the removal of excess buffer, the coated proteins were blocked with 100 µl of 
3% BSA in TBS-T for 2 hours at room temperature and incubated with the heat 
inactivated pAb diluted in 1% BSA for one hour at 37°C. After extensive washing with 
TBS-T, 100 µl of alkaline phosphatases-labelled goat anti-mouse IgG (1:2000 in 1% 
BSA) was added. The reaction was developed by addition of p-nitrophenyl phosphate 
(KPL, USA). The OD absorbance was read at 410 nm. The cut-off value of absorbance 
was calculated as average mean OD of negative samples ± 2 SD. The DENV-1 isolates 
showing 2-fold greater ELISA OD with pAb was identified as positive and strong 
binding. 
 
2.4.5 COMPETITION ELISA 
Equal amount and concentration of DENV-1 and DENV-2 virions (1:1) were mixed and 
pre-coated into the 96 well plates overnight as in 2.4.4. Excess buffer was removed and 
blocking of non-specific binding sites were done by adding 3% BSA, heat inactivated 
pooled pAb from DENV-1 and DENV-2 diluted with 1% BSA were added and 
incubated for 2 hours at 37°C. The plate was washed 3 times with 1 × TBS-T and 3 
times with 1 × TBS. Subsequently, 100 µl of alkaline phosphatases-labelled goat anti-
mouse IgG diluted 1:2000 in 1% BSA solution was added. Then, p-nitrophenyl 
phosphate substrate (100 µl) was added to develop the reaction. The absorbance value 
was determined at 410 nm with an ELISA micro plate reader. The cut-off value of 
absorbance was calculated as average mean OD of negative samples ± 2 SD.  
 
2.5 IMMUNE RESPONSE 
2.5.1 MICE IMMUNIZATION WITH RECOMBINANT PROTEINS 
A group of four BALB/c female adult mice (4 weeks old) (MP/23/02/2011/MBD®) was 
immunized intraperitoneally with a 50% emulsion of complete Freud’s adjuvant mixed 
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with 100 µg of purified recombinant proteins. The animals were housed in a 
temperature-controlled environment at 22°C – 24°C with 12 hours day-night cycles. 
The immunization was boosted twice: first with the same dose of recombinant proteins 
in 50% incomplete Freud’s adjuvant and the final without using adjuvant. The interval 
between the first, second and final immunization was ten days. Blood samples were 
collected through tail bleeding seven days after the last immunization. ELISA method 
was used to determine immune response. Final blood samples were obtained ten days 
after last immunization through heart puncture. pAb was harvested by centrifugation of 
clotted blood at 1800 x g for 5 minute and stored at -20°C until use. ELISA method was 
used to determine polyclonal antibody titres. The absorbance was read at 490 nm with 
an ELISA micro plate reader (Tecan Sunrise™, USA). The cut-off value for positive 
binding was calculated as average mean OD of negative samples ± 2 SD.  
 
2.5.2 IMMUNE RESPONSE AGAINST RECOMBINANT PROTEIN ON MICE 
Briefly, purified wild type mutant recombinant E (25 µg/ml) and their respective phage 
particles (2.5 × 10
6
 cfu/ml) were pre-coated onto 96-well plates (Costar, USA) in a 
carbonated buffer at 4°C overnight. The plates were blocked with 3% BSA for 2 hours 
at room temperature. Heat inactivated pAb two-fold dilution in 1% BSA was added 
after 5 times washing with TBS-T. The alkaline phosphatase-labelled goat anti-mouse 
IgG (100 µl) diluted 1:2000 solution was added. Then, 100 µl of p-nitrophenyl 
phosphate substrate was used to develop the plate. The absorbance was read at 410 nm 
with an ELISA micro plate reader. The cut-off absorbance value was calculated as 
average mean OD of standard negative samples ± 2SD. The ± 2SD was determined 
from microneutralization assay using mouse sera. The test serum showing a 2-fold rise 
in ELISA OD than that of the negative control was positive and significant, while serum 
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samples which shows two folds lower ELISA OD than that of the negative is negative 
and not significant for IgG. 
 
2.6 MICRONEUTRALIZATION ASSAY 
DENV isolates (5 × 10
2
 ffu/ml) were mixed in equal volumes of heat-inactivated 
serially diluted pAb (1:20 – 1:1280) and incubated at 37°C for one hour. Neutralization 
assay was performed as previously described(Twiddy et al. 2003). The cut-off value 
was determined by subtracting ± 2 SD from the average OD of standard negative 
control. The neutralizing titre is the maximum dilution below the cut-off value. To test 
the ability of pAb from immunized mice to neutralize or block dominant DENV-1 and 
DENV-2 circulating in Malaysia, microneutralization assays were performed. The pAbs 
were heat-inactivated for 30 minutes at 56°C using heating block. 
 
2.6.1 MICRONEUTRALIZATION OF DENGUE WITH POLYCLONAL SERUM 
Fifty microliters of each DENV isolates (5 × 10
2
 ffu/ml) was incubated with equal 
volume of serial dilution (1:20 – 1:1280) of the heat inactivated polyclonal serum 
samples and incubated at 37°C for one hour. Mixture of the virus and serum (100 µl) 
was transferred to overnight monolayers of C6/36 and Vero cells in a 96 well plates (3 × 
10
4
cells/ml). The plates were incubated at 28°C and 37°C in 3% and 5% CO2 for 4 days 
respectively. Then, the cells were fixed with 100 µl of cold ethanol/methanol (1:1) for 
30 minutes at 4°C. After removing the fixative and vigorously washed 10 times with 1 × 
PBS, the plates were incubated with rabbit raised hyperimmune serum for another 1 
hour at 37°C. After washing 10 times with 1xPBS, anti-rabbit IgG conjugated with 
alkaline phosphatase was added and incubated at room temperature for 2 hours. 
Subsequently, 100 µl of AP-substrate, p-nitrophenyl phosphate was added. The OD was 
read at 410 nm / 465nm wavelength. The cut-off value was determined by subtracting ± 
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2 SD from the average OD of standard negative control. The neutralizing titre is the 
highest dilution below the cut-off value.  
 
2.6.2 FOCI REDUCTION NEUTRALIZATION TEST (FRNT50) 
The FRNT50 assay was performed according to (Zandi et al. 2012) with minor 
modification. Briefly, heat-inactivated serum samples were diluted four-fold (1:20 to 
1:1,280) in tubes, with maintenance medium containing 2% FBS used as diluent. The 
serially diluted pAbs were incubated with an equal volume of virus suspension 3000 
ffu/ml for an hour at 37°C. Following that, the virus and serum mixture (200 µl) were 
added to the monolayers of C6/36 and Vero cells. The plates were incubated for 2 
hours, at room temperature. Overlay medium (1ml), containing 2% FBS and 1.5% 
carboxymethylcellulose (Sigma-Aldrich, USA) was added to the wells. The plates were 
incubated at 28°C and 37°C for 4 days, respectively. The foci were visualized as 
described in 2.1.4. The antibody titre was expressed as the reciprocal of highest serum 
dilution yielding50% reduction in foci formed (FRNT50). 
 
2.6.3 NEUTRALIZATION ESCAPE 
DENV virions were continuously propagated in growth medium supplemented with 
pAb at normalized dilution (1:80) that yields 50% reduction in foci formed. Briefly, 
3000 ffu/ml of DENV virions were mixed with 50 µl of diluted pAb for one hour at 
37°C and then briefly centrifuged before transferred onto C6/36 and Vero cells for one 
hour at room temperature with gentle rocking. After removing excess media, the plate 
was incubated at 28°C or 37°C in 3% and 5% CO2 for 4 days corresponding to the 
insects or mammalian cell line. The supernatant was harvested and 100 µl were mixed 
with 50 µl of the diluted pAb followed by passaging for the second time. This 
propagation was repeated thrice. After the each round of propagation, focus formation 
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assay was performed as previously described (Russell and Nisalak 1967; Wong, et al. 
2007) to determine the foci reduction. The viral RNA from passage four was obtained 
and E was sequenced and compared. 
 
2.7 SEQUENCING ANALYSIS 
2.7.1 SEQUENCING AND ANALYSIS OF E 
DENV-1 and DENV-2 strains shown in Table 2.1 were obtained from UMMC virology 
repository. Sequencing was performed in-house using BigDye Terminator kit v.3.0 
(Applied Biosystems, Bedford, MA) according to the manufacturer`s. Analysis of 
nucleotide and amino acid sequences were performed using Clustal × V3.1 (Larkin, 
Blackshields et al. 2007), GeneDoc, MEGA 5.0 (Tamura, et al., 2011) programme 
respectively.  
 
2.7.2 SEQUENCING ANALYSIS OF SITE DIRECTED MUTAGENESIS CLONES 
Similarly, purified phagemid displaying DENV-1 and DENV-2 recombinant gene 
cassette and site directed mutagenesis clones were sequenced as in 2.7.1. The purified 
phagemid were sequence to determine whether variant mutants were generated and 
whether there was shifting in the reading frame. 
 
2.8 MOLECULAR MODELLING 
The nucleotide sequence of the DENV E and the molecular location of amino acid 
substitutions were modelled on the 3D structure of the DENV-2 E (SWIS-prot PDB 
code: 1ok8) using the program FirstGlance in Jmol version 1.44 
(http://bioinformatics.org/firstglance/fgij/). The program was used to determine the 
locations of the major amino acid residues substituted with the minor residues. The 
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relative distance between the amino acid residues, at the same monomer on envelope 
homodimers were equally read. 
 
2.9 STATISTICAL ANALYSIS 
The ELISA and FRNT results were analysed using Graph Pad PRISM 5.0 (Graph Pad 
Software Inc., San Diego, CA, 2005). Mean differences were calculated using ANOVA 
followed by Tukey’s post-hoc test where appropriate. The levels of significance are 
denoted as the following: *P<0.05. 
 
2.10 CHEMICALS AND REAGENTS 
 All chemicals except when stated were purchased from Sigma, USA and all organic 
solvents or solutions were purchased from BDH, UK.  All culture media and tissue 
culture reagents were obtained from Flowlab, Australia.  Monoclonal antibodies were 
purchased from BDH Pharmgen, USA; Cell Signaling Technology, USA and Sigma, 
USA. 
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3.0 RESULTS 
The overall objective of the proposed study is to investigate the antigenic evolution of 
DENV in Malaysia. To achieve this, site directed mutagenesis approach were used to 
create mutations on E gene cassettes displayed on phage g3p minor coat protein. The 
mutated phage particles and their corresponding E were used in competitive binding 
assays to determine the effects of mutations engineered on E on the mosquito (C6/36) 
and mammalian cells (Vero). The polyclonal antibodies were generated against gene 
cassettes displaying recombinant E of the Malaysian DENV-1 and DENV-2 in BALB/c 
mice. The corresponding polyclonal antibodies were used for binding and neutralization 
escape studies using dominant DENV-1 and DENV-2. This is important for determining 
positions on E likely to influence future antigenic evolution of DENV-1 and DENV-
2.Functional assays were employed to test the immunological properties of the 
polyclonal antibodies and to identify the antigenic site on E of the dominant DENV-1 
and DENV-2 circulating in Malaysia that could play a significant role in neutralization 
escape and selection of dominant strains likely to evolve in the future. 
 
In the present study, DENV-1 and DENV-2 antigenic evolution were investigated in 
vitro. The results and data analysis between DENV-1 and DENV-2 used in the study 
were reported simultaneously. However, the results and data presented are independent 
of each genotype, because the two genotypes have different evolutionary patterns. The 
results obtained from the study were inferred between the two genotypes in the course 
of this study. 
3.1 DENV-1 AND DENV-2 E GENE CASSETTES 
The following series of experiments were performed to construct gene cassettes 
displaying the envelope-coding regions of DENV-1 and DENV-2. Dominant strains 
from DENV-1 and DENV-2 were explored from the Malaysian genome-sequencing 
80 
 
project. The genetic variability was determined. A variable sites coding for predicted 
surface exposed amino acids known to influence antigenic evolution were selected. 
Successful mutations on these positions were created by site-directed mutagenesis and 
determined using Sanger sequencing. The gene cassettes were displayed as recombinant 
phage particles. Phages were rescued using helper phage and rescue phage was titrated. 
The titres were quantified by colony forming unit/viable plate count. The antigenic 
proteins displayed by the recombinant phage particles were expressed following 
infection of E.coli HB2151. The expressed proteins were visualized using immune blot 
assay. The proteins were purified using affinity gel matrix. 
 
3.1.1 VARIABLE ANTIGENIC SITES ON E CODING REGION OF DENV-1 AND DENV-2 
The dominant DENV strains were defined as the major endemic genotypes circulating 
in natural population. The sequences of the dominant strains presenting with one or 
more variable site on the predicted surface exposed amino acid were considered as an 
antigenic informative site. From the analysis of both DENV-1 and DENV-2 dominant 
strains, six antigenic informative sites each were determined across the three major 
antigenic domains (Table 3.1 and 3.2).  The six positions were within or adjacent to 
DENV-1 and DENV-2 known antigenic determinants spread across the E. The amino 
acid sequences of the dominant dengue virus strains were shown in appendix B (DENV-1) and 
appendix C (DENV-2). Mutations introduced into the gene cassettes were based on these 
selected positions and they mimic published data and rare amino acids, amino acid 
infrequent in the strains that co-circulate along with the dominant strains (Table 3.1 and 
3.2). 
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Table 3.1: Surface exposed amino acid on the E of dominant DENV-1 strains 
 
 Major AAs are amino acids found on the dominant isolates frequent during an 
outbreak 
 Minor AAs are amino acids found on the less frequent isolates circulating with 
the dominant isolates during an outbreak 
 
 
 
 
 
   
 
 
 
Antigenic informative site and their amino acid residues 
Antigenic domain EDI EDII EDIII 
AAs position E161 E171 E297 E272 E305 E390 
Major AAs residue T S M T S S 
 
D1.36000/05/GIa T S M T P N 
D1.11177/97/GIb T S M T S S 
D1.59280/05/GIc T T M T S S 
D1.10245/97/GII I S I T S S 
D1.59266/97/GIII I S V M L S 
 
Minor AAs residue S A L S P R 
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Table 3.2: Surface exposed amino acid on the E of dominant DENV-2 
 
 Major AAs are amino acids found on the dominant isolates frequent during an 
outbreak 
 Minor AAs are amino acids found on the less frequent isolates circulating with 
the dominant isolates during an outbreak 
 
 
 
 
Antigenic informative site and their amino acid residues 
Antigenic domain EDI EDII EDIII 
AAs position E164 E176 E52 E71 E335 E393 
Major AAs residue I T H A I K 
 
D2.14281/97/Cosmopolitan I T H A I K 
D2.14245/97/Cosmopolitan V T H A I K 
D2.16041/98/Asian I I T Q E V K 
D2.1704378/07/Cosmopolitan I T H A I K 
D2.1877347/07/Cosmopolitan I T H A I K 
 
Minor AAs residue L S K N L M 
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3.1.2 AMPLIFICATION OF E 
The envelope-coding regions of the virus were amplified from total RNA extracted from 
one of the circulating prototype of the respective dominant strains. The amplification 
uses combinations of degenerate primers. As shown in Figure 3.1A, all primer amplified 
DENV-1 and DENV-2 E (1485 bp).  
 
3.1.3 AMPLIFICATION OF GENE CASSETTES 
Amplification of gene construct was performed as in 3.1.2 using specific primers. The 
combinations amplified a 1232 bp and 1532 bp fragments corresponding to DENV-1 
and DENV-2 respectively (Figure 3.1B &3.1B). The total amino acid residues for the 
respective gene cassettes were 403 and 505 (excluding restriction sites) with estimated 
molecular mass of 44 kDa and 56 kDa for DENV-1 and DENV-2, respectively. The 
amplified gene cassettes shown in Figure 3.1B and 3.1C contained the engineered 
AlwNI and Bsp1208 restriction sites at N-terminal and C-terminal ends corresponding to 
the sfI and NotI restriction sites on pCANTAB5E phagemid vector accordingly. This 
enables fusion of the gene cassettes to the M13 minor g3p coat protein and displayed as 
antigenic proteins. There was also 24bp FLAG M2
®
 tag fusion peptide at the 3` ends of 
the gene cassettes. The FLAG M2
®
 tag was engineered to enable purification and 
detection of purified proteins with anti- FLAG M2
®
 monoclonal antibody. The results 
showed the primers amplified the required E and the gene cassettes at expected band 
sizes. 
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Figure 3.1. DENV-1 and DENV-2 amplified E coding regions. The Figures show 
amplified genes coding for DENV-1 and DENV-2 E. (A) Amplification of genes coding 
for DENV-1 and DENV-2 envelope regions: M= marker, lane 1 and 2= DENV-1, lane 3 
and 4= DENV-2.  (B) Gel electrophoresis of amplified DENV-1 truncated E coding 
region from DV1.rEwt.pCANwith an approximate DNA band size of 1232 bp and 
DENV-2 complete E coding regions DV2.rEwt.pCANwith an approximate band size of 
1532 bp in duplicate obtained using Bioanalyzer (Implen, Germany). The band varies 
due to RNA concentration used from 1ul to 2ul respectively. 
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(A) 
 
 
(B) 
 
 
 
 
 
 
86 
 
 
3.1.4 RECOMBINANT PHAGE MUTANTS 
To generate the recombinant phage mutant, the wild type recombinant phagemid 
(rEwt.pCAN) were mutated by site directed mutagenesis. The recombinant phagemid 
displaying mutated gene was transformed into TG1 bacteria cells. To determine whether 
the transformed TG1 bacteria contained the recombinant phagemid with desired 
mutations on the gene cassette, direct colony amplification was performed on randomly 
selected single colonies. Gene specific primers were designed to amplify only a 
fragment of the DENV-1 and DENV-2 gene inserts (~ 1203 and 1503 bp). The results 
showed that 90 percent of the bacterial colonies screened contained a recombinant 
phagemid with the desired gene cassette construct at the expected sizes. The results 
suggest the recombinant phagemid had been successfully mutated (Figure. 3.2 A/B).  
Analyses of the amplified amplicons showed with the exception of clones rE171.pCAN 
(5) and rE390.pCAN (5) from the DENV-1, rE176.pCAN (5) andrE393.pCAN (4) from 
the DENV-2, all six clones tested were positive and had the correct gene insert.  The 
confirmed positive colonies were sequenced and generated mutations were confirmed. 
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Figure 3.2. Screening of amplified amplicons after site-directed mutagenesis. (A) 
DENV-1 and (B) DENV-2 amplified amplicons from the recombinant phagemid after 
site-directed mutagenesis: The DNA size markers and expected band sizes determined 
using Bioanalyzer electrophoresis gel are shown on the gel picture. The test samples 
were labelled as follows; 
 
Lanes  (A) DENV-1            (B) DENV-2 
1-6  rE161.pCAN   rE52.pCAN 
7-12  rE171.pCAN   rE71.pCAN 
13-18  rE272.pCAN   rE164.pCAN  
19-24  rE297.pCAN   rE176.pCAN 
25-30   rE305.pCAN   rE335.pCAN 
31-36   rE390.pCAN   rE393.pCAN 
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(A) 
 
(B) 
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3.1.5 SEQUENCING AND CONFIRMATION OF MUTATION 
DENV sequencing and analysis was performed to identify the nucleotide sequences of 
each mutated position after site directed mutagenesis. As mentioned above, six surface 
exposed rare amino acids on the gene cassettes expressing DENV-1 and DENV-2 E 
were mutated. Purified phagemid from the positive colonies in 3.1.4were sequenced. 
They were evaluated to confirm amplification and mutation at the desired antigenic 
position positions. From result analysis of the sequencing results it was confirmed that 
the nucleotides at the selected positions and their corresponding amino acids were 
successfully mutated compared with the wild type recombinant phagemid with the 
original prototype gene. The sequence traces for the wild type and that of the mutated 
recombinant gene cassettes showed conserved sequences. Mutations were observed at 
the expected mutated amino acid positions (see appendix D (DENV-1) and appendix E 
(DENV-2) for chromatograms). These results confirmed a successful mutation and 
introduction of the single amino acid at the targeted positions on the gene cassettes of 
both DENV-1 and DENV-2. 
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3.1.6 PHAGE TITRE OF RECOMBINANT PHAGE PARTICLES DISPLAYING ANTIGENIC 
PROTEINS 
 In order to determine the wild type and mutated phage titre, the TG 1 bacteria 
transformed with phagemid were rescued using the M13K07 helper phage. The wild 
type recombinant phage particles were designated as DV1.rEwt.phand DV2.rEwt.phand 
their titre was determined. After phage rescue by serial dilutions and viable plate count, 
the titres were found to be approximately2.3 x 10
10
 and 5.4 x 10
9
 cfu/ml for DENV-1 
and DENV-2 respectively.  
 
The phage titre of the mutated phage particles from DENV-1 and DENV-2 after rescue 
with helper phage were determined and quantified. From the results, phage titres of the 
mutants were slightly lower in comparison with the wild type phages. The titre ranges 
from 1 x 10
9
 to 1 x 10
10
 colony forming unit per millilitre (Table 3.3). Results obtained 
showed that from a known amount of helper phage of 3.0 x 10
10
 cfu/ml added as the 
starting material to infect the transformed bacteria, 1 x 10
9
 – 1 x 1010cfu/ml (30% - 
80%) of the helper phage infect the transformed bacterial cells and were packaged into 
mature phage particles. The mean difference in the phage titre between the wild type 
and the mutants was 10% compared with the starting phage titre of approximately 55%.  
These results confirmed the successful infection of the transformed bacteria with the 
helper phages. An average recovery rate of 1 x 10
9.5
cfu/ml of phage particles in both 
DENV-1 and DENV-2 were packaged accordingly. The purified recombinant phage 
particles were used for binding tests as well as expression of the respective recombinant 
antigenic proteins. 
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Table 3.3: Quantitative phage titre of wild type and mutant phage particles after rescue with helper phages 
 
 
 
 
 
 
 
 
 
 
DENV-1 
 
DV1.rEwt.ph rE161.ph rE171.ph rE272.ph rE297.ph.ph rE305.ph rE390.ph +ve ctr 
Phage titre (cfu/ml) 
 
2.3 ×10
10
 5.3×10
9
 8.2×10
9
 4.2×10
9
 3.2×10
9
 7.7×10
9
 9.2 ×10
9
 2.2×10
10
 
DENV-2 
 
DV2.rEwt.ph rE52.ph rE71.ph rE164.ph rE176.ph rE335.ph rE393.ph +ve ctr 
Phage titre (cfu/ml) 
 
5.4×10
9
 5.2 ×10
8
 6.6 ×10
9
 6.0 ×10
9
 2.1 ×10
10
 9.2 ×10
9
 7.0 ×10
9
 2.2×10
10
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3.1.7 RECOMBINANT PHAGE PARTICLES EXPRESSING WILD TYPE ANTIGENIC PROTEINS 
For the expression of the recombinant proteins cloned in the mid phage particles, the 
recombinant phage were precipitated and purified. The expression host HB2151 E. coli, 
was infected with the purified phage particles. Single colony from the infected bacteria 
was grown and induced by IPTG; expressed proteins were purified from the lysate 
prepared using a bacterial non-denaturing extraction formulation. The purity of the 
protein from both columns was comparable and was read to be in the range of 210µg – 
275µg per litre of an induced bacterial culture (Table 3.4). 
 
Twenty-five micrograms of the purified proteins were electrophoresed on 10% SDS-
PAGE. The wild type antigenic proteins were designated rEnvWT. The expected bands 
were confirmed by immuno blotting using anti-FLAG M2
®
 monoclonal antibody. As 
shown in Figure 3.3 A/B, the FLAG-tagged antigenic proteins were separated at the 
correct molecular mass of 44-kDa for DENV-1 and 56-kDa for DENV-2. The results 
showed the wild type DENV-1 and DENV-2 E expressed as soluble proteins, detected, 
and recognized by the anti-FLAG M2
®
 monoclonal antibody (Figure. 3.3 A/B). The 
recombinant proteins were purified using the affinity column which bound to the FLAG 
M2
®
 tag peptide engineered on the proteins. 
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Table 3.4:  The expressed recombinant protein concentrations 
 Not successfully expressed 
 
 
 
 
 
 
 
 
 
 
 
 
DENV-1 
 
DV1.rEnvWT rEnv161* rEnv171 rEnv272 rEnv297* rEnv305 rEnv390 
Protein 
Conc. 
210µg/L - 78µg/L 196µg/L - 254µg/L 207µg/L 
DENV-2 
 
DV2.rEnvWT rEnv52 rEnv71 rEnv164 rEnv176 rEnv335 rEnv393 
Protein 
Conc. 
270µg/L 211µg/L 201µg/L 116µg/L 218µg/L 202µg/L 271µg/L 
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Figure 3.3. Expression and purification of phage displayed recombinant DENV (A) 
Immuno blot of DV1.rEwt expressed and displayed on phage M13 g3p attachment 
protein. Peroxidase conjugated anti-FLAG M2® monoclonal antibody was used as the 
secondary antibody. The monoclonal antibody bound specifically to the 44 kDa 
recombinant E antigenic proteins indicated by the arrows. (1: purified protein, 2: 
unpurified lysate (3 hours induction), 3: unpurified (6 hours induction), 4: uninduced 
lysate).). (B) Immuno blot of DV2.rEwt expressed and displayed on phage M13 g3p 
attachment protein. The monoclonal antibody bound specifically to the 56 kDa of the 
recombinant E antigenic proteins indicated by the arrow.  Detection was performed as 
described in (a) above (1: unpurified, 2: whole cell lysate (3 hours induction), 3: 
uninduced lysate, 4-5 purified lysate (6 hour induction).  
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(A) 
 
 
 
(B) 
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3.1.8 RECOMBINANT PHAGE PARTICLES EXPRESSING MUTANT ANTIGENIC PROTEINS 
The expression of soluble proteins displayed by the mutated gene cassettes was also 
determined. The positive recombinant phagemid verified after site-directed mutagenesis 
were transformed into HB2151 E. coli, rescued and purified as in 3.1.7. Twenty-five 
micrograms of the expressed proteins were electrophoresed on 10 % SDS-PAGE. The 
recombinant protein was designated according to their respective amino acid positions 
(Table 3.4). The expected polypeptides were confirmed by immuno blotting using anti-
FLAG M2
®
 monoclonal antibody. In figure 3.4 A/B, eluted fraction contained 44kDa 
and 56 kDa polypeptides, which corresponded to pure recombinant protein as observed 
in the wild type proteins. Four recombinant Es from DENV-1 (rE171, rE272, rE305 and 
rE390) and all six recombinant Es from DENV-2 (rE52, rE71, rE164, rE176, rE335 and 
rE393) displayed, expressed and purified as a soluble protein. They were detected and 
recognized by the anti-FLAG M2
®
 monoclonal antibody. The purified proteins were 
quantified using the micro BCA kit. The quantities of the purified proteins ranged 
between 78 µg to 270 µg of proteins per litre of bacterial culture. The expression 
efficiency varies between each clone. The proteins were used for both binding assay and 
generating pAb in mice. The rE161 and rE297 were not successfully expressed. Taken 
together, the results confirmed the expression of soluble antigenic proteins by HB2151 
E. coli and displayed on g3p minor proteins coat of the M13K07 infected 
bacteriophages. 
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Figure 3.4. Expression and purification of recombinant E from mutated DENV-1 and 
DENV-2  
(A) Immuno blot of mutant DENV-1 recombinant proteins expressed and displayed on 
phage M13 g3p attachment protein. Mutant recombinant proteins were detected by anti-
FLAG M2
(R) 
antibody. Arrows indicate the presence of the 44kDa recombinant protein.  
The monoclonal antibody binds specifically to the 44 kDa of the recombinant E 
antigenic indicated by the arrow (2= pooled rEnv161 and rEnv297). (B) Immuno blot of 
mutant DENV-2 recombinant E antigenic proteins expressed and displayed on phage 
M13 g3p attachment protein. The monoclonal antibody binds specifically to the 56 kDa 
of the recombinant E antigenic proteins indicated by the arrow (1= pooled follow 
through from the purified proteins). All purified proteins were indicated by their 
designated names. 
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(A) 
 
 
 
(B) 
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3.2. CHARACTERIZATION OF RECOMBINANT PHAGE DISPLAYING MUTATED CLONES 
Having successfully generated the starting materials for the proposed study, the 
following series of binding studies were performed. Firstly, to determine the optimum 
binding of the wild type and mutated phage particles by bacteria colony forming 
count/viable plate count. Secondly, to determine the effects of altered amino acids on 
binding affinity and specificity of the phage particles to mosquito (C6/36) and 
mammalian cells. Finally to evaluate the binding affinity of recombinant proteins and 
dengue virions against polyclonal antiserum generated in mice immunized with the 
respective recombinant proteins. The binding was assessed using ELISA method.  The 
objectives of this experiment are to establish the role of the altered amino acid positions 
on the recombinant mutants on receptor binding to C6/36 and Vero cells. 
 
3.2.1 OPTIMUM BINDING CONCENTRATION OF RECOMBINANT PHAGE PARTICLES 
Binding studies were first performed to determine the optimum titre of the recombinant 
phage particles that would bind to C6/36 and Vero cell lines. Following incubation of 
the wild type recombinant phage particles with C6/36 and Vero cell lines using three 
different phage titres; 2.5 x 10
5
 cfu/ml, 2.5 x 10
6
 cfu/ml and 2.5 x 10
7
 cfu/ml; the 
recombinant phage particles recovery varies as the titre of the phage particles differed 
across the two cell lines (Figure 3.5A/B). An estimated average percentage of phage 
titre recovery, which bound to the targeted cell receptors on C6/36 and Vero cell lines in 
increasing order, was 5.1%, 24% and 9.6% for phage displaying DENV-1 and 4.05%, 
28.1% and 10.72% for DENV-2 accordingly. The binding was relatively similar in both 
C6/36 and Vero cells with no significant differences. The only notable difference 
between the cell lines were observed at the maximum phage titre of 2.5 10
7
 cfu/ml in 
DENV-2. From the results, the optimum phage titre on the C6/36 and Vero cells was 
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2.5 × 10
6
 cfu/ml. The 2.5 × 10
6
 cfu/ml was used throughout the subsequent binding 
assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 
 
 
 
 
 
 
 
 
Figure 3.5. Binding of (A) DV1.rEwt.ph and (B) DV2.rEwt.ph.C6/36 cell lysate coated 
onto 96-well plates were used. The cells were fixed using paraformaldehyde. Initially 
cells were incubated with 2.5 x 10
5
, 2.5 x 10
6
 and 2.5 x 10
7
 cfu/ml, for 2 hours at 37°C. 
TG1 bacteria (mid-log) were added and further incubated for 30 minutes at 30°C after 
vigorous washing with 1x PBS buffer to remove unbound phage. The binding was 
quantified using colony forming count/viable plate count and expressed as colony count 
per unit (cfu). The control used 2.5 x 10
6   
cfu/ml of A10B. Binding of truncated DENV-
2 E fragments displayed on M13 phages.    
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3.2.2 EVALUATION OF BINDING ASSAY OF RECOMBINANT PHAGE PARTICLES 
DENV-1: The mutations on E are specific on each individual clone. Their effects were 
investigated. To this aim, the binding of DENV-1 recombinant phage on C6/36 and 
Vero cell lines were evaluated. 2.5×10
6
 pfu/ml of purified recombinant phage particles 
were added to fixed cells in 96 well plates and unbound phage were vigorously washed 
and mid-log bacteria were added and spread onto 2×YT-AG plates overnight at 30°C. 
The phage binding to two DENV-1 susceptible cells lines, C6/36 and Vero did not 
differ significantly (Figure 3.6). All E mutant phage displayed reduced binding 
compared to the DV1.rEwt.ph in both cell lines. The binding efficacies of rE272.ph and 
rE390.ph to both C6/36 and Vero cells were reduced significantly compared to 
DV1.rEwt.ph. Although the binding efficacies of rE161.ph, rE297.ph and rE305.ph 
were also reduced compared to DV1.rEwt.ph, the differences were not statistically 
significant, suggesting that mutation at these positions did not affect binding. No 
measurable binding with negative control (A10B) was observed. These results 
demonstrated that the binding affinity and interaction of rE272.ph and rE390.ph to 
C6/36 and Vero cell receptors were affected by the alteration of single amino acid at 
these positions on the DENV-1 recombinant E gene.   
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Figure 3.6. Binding affinity of DENV-1 recombinant phage particles to C6/36 and Vero 
cells: Binding of the phage particles to the cells before precipitation and after phage 
precipitation with pooled polyclonal antibodies from the wild type and recombinant E at 
1:80 and 1:640 dilutions. Cell viable count was used and average mean differences were 
calculated using ANOVA followed by Tukey’s multiple comparisons for each sample 
with DV1.rEwt.ph before precipitation. (*) Denotes level of significance at p<0.05. 
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Since the primary function of the neutralizing antibodies is to bind to antigenic 
determinant and block proteins binding to cell receptors, we next assessed how the pAb 
generated against the recombinant phage displaying the E mutant will affects binding to 
insects and mammalian cells. The pAb generated from the wild type and mutant E were 
each pooled and used to precipitate the recombinant phage at 1:80 and 1:640 dilutions. 
The specificities of these interactions were assessed, for the recombinant phages, by 
comparing against the binding efficacies of DV1.rEwt.ph prior to precipitation. After 
precipitation with the pooled polyclonal antibodies at 1:640 dilutions, all recombinant 
phage displayed reduced binding to C6/36 cells (Figure3.6). However, only rE272.ph 
and rE390.ph showed significant reduction. Similarly, rE272.ph and rE390.ph exhibited 
significantly reduced binding compared to rEwt.ph binding to Vero cells. At 1:80 
dilutions, all recombinant phages showed up to four-fold reduction in the binding to 
both cells, except for rEwt.ph binding to Vero cells. These results suggest that the 
pooled pAb could block and reduce the binding of the DV1.rEwt.ph and the mutated E, 
specifically rE272.ph and rE390.ph from binding to C6/36 and Vero cells.  
 
DENV-2: In a similar setting, binding using DENV-2 recombinant phage to fixed C6/36 
and Vero cells was evaluated. The phage binding to two DENV-2 susceptible cells 
lines, C6/36 and Vero did not differ significantly (Figure 3.7).  From the results, 
rE71.ph, rE164.ph and rE335.ph mutants displayed highest binding compared to the 
DV2.rEwt.ph recombinant phage binding to both cell lines. The binding of rE176.ph 
and rE393.ph to both C6/36 and Vero cells were significantly reduced compared to 
DV2.rEwt.ph. No measurable binding with negative control (A10B) was observed. 
These results demonstrated that the binding affinity and interaction of 
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rE52.ph, rE176.ph and rE392.phto C6/36 and Vero cells were affected by the alteration 
of single amino acid at the respective positions on the DENV-2E cassettes.    
 
The DENV-2 recombinant phage particles were precipitated with the pooled pAb 
generated against the displayed proteins. The specificities of these interactions were 
assessed by comparison with the DV2.rEwt.ph prior to precipitation. However, in 
DENV-2, after precipitation with 1:640 dilutions of the pooled polyclonal antibodies, 
two-fold reduction in the number of colonies formed at ≤1:640 were observed (Figure 
3.7). All recombinant phage displayed showed four-fold reduction at 1:80 dilutions for 
both cell lines. The rE71.ph, rE164.ph and rE335.ph did not exhibited significantly 
reduced binding compared to DV2.rEwt.ph before precipitation, but significantly 
reduced after precipitation with pAb (Fig. 3.7). These results suggest that the pooled 
pAb could block and reduce the binding of the recombinant phage displaying the wild 
type and E mutants, especially rE71.ph, rE164.ph and rE335.ph from binding to C6/36 
and Vero cells. 
 
Taken as a whole, these results showed binding of the phage particles expressing 
DENV-1 and DENV-2 E was affected by the mutations introduced at certain positions 
of the DENV recombinant E.  
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Figure 3.7. Binding of DENV-2 recombinant phage particles to C6/36 and Vero cells: 
Binding of the phage particles to the cells before precipitation and after phage 
precipitation with pooled polyclonal antibodies from the wild type and recombinant E at 
1:80 and 1:640 dilutions. Bacterial cell viable count was used and average mean 
differences were calculated using ANOVA followed by Tukey’s multiple comparisons 
for each sample with DV2.rEwt.ph before precipitation. (*) Denotes level of 
significance at p<0.05. 
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3.2.3 REACTIVITY OF DENV ANTIGEN WITH POLYCLONAL ANTIBODY 
The recombinant phage particles were able bind to mosquito and mammalian cell lines. 
The binding was affected when amino acids were altered. Precipitating the phages with 
antibodies showed statistically reduced binding of the phages. Next, BALB/c mice were 
immunized with the purified recombinant proteins to assess the specific antibody 
response against the E mutants. This is to test whether the mutations affects 
recombinant proteins binding to pAb. The results are shown in figure 3.8 A/B. Overall, 
the recombinant E from DENV-1 induced high immune responses in BALB/c mice, 
producing pAb as detected by ELISA (Figure 3.8A). The DV1.rEnvWT produced 
antibodies at titre up to 1:1024 dilution above the ELISA cut-off value of 1.24±2SD. 
Amongst the recombinant E mutants, the pAb from the mice immunized with rEnv305 
showed a slightly higher titre value at 1:256 serum dilutions compared to rEnv272, 
rEnv171 and rEnv390 (all at >1:256 respectively). Hence, the read antibody responses 
induced from DV1.rEnvWT and mutants were at comparable levels. The negative 
control containing recombinant phage particles expressing the gene cassette alone 
(pAb.M13) did not induce detectable immune response in the BALB/c mice.  
 
Similarly, immune responses against the recombinant E from the DENV-2 induced high 
immune responses in BALB/c mice as detected above the ELISA cut-off value of 
1.13±2 SD.  The pAbs titre were in the range of >1:256, >1:512, >1:512, 1:128, >1:256, 
1:512 and 1:256 for pAb.rEnv52, pAb.rEnv71, pAb.rEnv164, pAb.rEnv176, 
pAb.rEnv335 and pAb.rEnv393respectively (Figure 3.8B).  
 
The result suggests that the DENV-1 and DENV-2 recombinant antigenic proteins 
displayed by the phage particles induced immune responses in BALB/c mice. It is 
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apparent also, that the recombinant phage particles expressing the gene cassettes does 
not induced detectable immune response in BALB/c mice. The immune response was 
significant at p<0.05 and below the ELISA cut-off value of 1.24±2 SD and 1.13±2SD 
for DENV-1 and DENV-2 respectively.   
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Figure 3.8. Dose response curve of pAb in BALB/c mice immunized with the (A) 
DENV-1 and (B) DENV-2 wild type or mutant recombinant E. Sera from 4 mice per 
group were collected 1 week after last immunization and tested by ELISA. Plates were 
coated with wild type E and immobilized with pAb against wild type and mutant E. 
Antibody titres were expressed as the average mean OD of negative samples ± 2 SD. 
The ELISA cut-off value was 1.24±2SD and1.13±2SD for (A) DENV-1 and DENV-2 
respectively. The values shown are means of duplicate assays. pAb.M13 is pooled 
recombinant phage particles and (-ve) represents serum samples from non-immunized 
mice. 
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3.2.4 BINDING AFFINITY OF ANTISERA AGAINST DENV 
The pAb generated by immunizing mice with recombinant protein may not bind to the 
dominant DENV-1 and DENV-2 strains since they were generated using recombinant E 
with mutations at the antigenic regions. To identify the antigenic determinants the pAb 
binding sites were mapped by determining the binding to DENV-1 and DENV-2 strains. 
The aim is to examine the mutated residues leading to reduced or loss of binding to 
DENV-1 and DENV-2. 
 
In DENV-1, the neutralization efficiency of the pAb varied across the different DENV-
1 strains tested (Figure 3.9A). The pAb from DV1.rEwt displayed reduced 
neutralization to two DENV-1 strains: the D1.59266 and D1.59280. The pAb.rE272 and 
pAb.rE390 also exhibited significantly decreased neutralization to D1.59266 and 
D1.59280. The pAb recognized their corresponding antigenic proteins with high 
affinity. The results indicate that mutations at E272 and E390 reduced the binding of the 
pAb generated to the antigenic determinant in DENV-1 (D1.59266 and D1.59280 
genotypes). The pAb.rE171 and pAb.rE305 displayed efficient binding to all of the 
DENV-1 isolates tested, suggesting that mutation at these residues were antigenically 
less crucial. There was significantly reduced binding when the polyclonal antibody were 
mapped against the D2.14281 genotype. 
Using similar approach, the binding efficiency of the pAb varied across the different 
DENV-2 strains tested (Figure 3.9B). The pAb.DV2.rEwt displayed significant binding 
to all DENV-2 strains. The pAb.rE52, pAb.rE164 and pAb.rE176 displayed reduced 
binding when mapped against DENV-2 (D2.16041) Asian 1 strain (Figure 3.9B). The 
pAb.rE164 and pAb.rE335 also exhibited significantly decreased binding to 
(D2.1877347) Cosmopolitant strain. Consequently, the pAb recognized their 
corresponding antigenic proteins with high affinity. But, pooled pAb raised from 
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recombinant DENV-1 E did not bind to any of the DENV-2 isolates, suggests that the 
pAb rose using the DENV-2 E here are not cross-reactive with DENV-1. Therefore, the 
results here suggest that mutations on rE52, rE164 and rE176 affected the binding of the 
pAb to the antigenic determinant on D2.16041 genotype. Subsequently, mutations 
generated on rE164 and rE335 affected binding to D2.1877347 strain. The pAb.rE71 
and pAb.rE393 displayed efficient binding to all of the DENV-2 isolates tested, 
suggesting that mutation at these residues were antigenically less crucial. 
In a competitive binding ELISA of equal ratio of DENV-1 and DENV-2 virion binding 
to polyclonal antibody DENV-2 virion does not alter the affinity of DENV-1 pAb 
binding towards antigenic determinant on DENV-1. The result was same as the result on 
3.2.4 as shown in figure 3.9A/B. The same was observed in DENV-2 binding in the 
presence of DENV-1. 
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Figure 3.9A/B. Binding of pAb to DENV: The binding was determined using ELISA. 
Briefly, (A) DENV-1 and (B) DENV-2 virions were coated onto 96-well plate followed 
by immobilization with the indicated pAb. The corresponding antigenic proteins were 
used as positive control. Data represent mean of SEM of the triplicates. The data were 
analysed using Tukey’s multiple comparisons test. (*) Denotes significant difference 
(p<0.05). 
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3.3 NEUTRALIZATION ASSAY 
The results presented so far demonstrated that mutations at positions E272 and E390 of 
the DENV-1 E affected binding of the respective recombinant phages to C6/36 and the 
Vero cells. The same mutation generated pAb that had reduced binding to two of the 
dominant DENV-1 strains. In DENV-2, mutations at E52, E164 and E 393 affected 
phage binding to C6/36 and Vero cells. On the contrary, binding of pAb generated using 
recombinant E52, E164 and E176 affects binding on Asian I strain and E164 and E335 
on one of the Cosmopolitan strain of the dominant DENV-2. Thus, these mutations on E 
affected the respective antibody binding to some, but not all the dominant dengue strain 
of the same serotypes. In the following investigation microneutralization assay was 
performed to determine the neutralizing effects of the pAbs against DENV-1 and 
DENV-2 in vitro using C6/36 cells. The microneutralization results were validated 
using Focus Reduction Neutralization Test (FRNT50) on Vero cells.  
 
3.3.1 MICRONEUTRALIZATION CAPACITY OF POLYCLONAL ANTIBODIES AGAINST 
DOMINANT DENV STRAINS 
The investigation aimed to determine possible DENV strains that could evade antibody 
neutralization in the future. The results from Microneutralization/FRNT50 assays are 
shown in Table 3.5. Microneutralization result performed on C6/36 was presented as the 
highest pAb titre whereas the FRNT50 results using Vero cells were presented as the 
percentage of the total number of foci formed corresponding to the highest titre on 
microneutralization. From the result, the pAbD1wt and the mutant recombinant E from 
DENV-1 neutralized and blocked infection of D1.11177, D1.10245, and D1.36000 to 
the C6/36 cell line (Table 3.5). The dilution varied across pAbs as well as between the 
strains; the range was from 1:80 to 1:640 antibody titres. 
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In the Focus Reduction Neutralization Test on Vero cells similar effects were observed 
when compared with the corresponding microneutralization assay results (Table 3.5, 
Figure 3.10). The reduction in the number of foci is equivalent to two-fold reduction 
(74% – 95% foci reduction) of the virus titre of D1.11177, D1.10245, and D1.36000 in 
the presence of all the pAbs (FRNT50).  However, D1.59266 and D1.59280 were 
completely neutralized by all the pAbs tested at pAb titre >1:320 – 1:640. An unrelated 
polyclonal serum antibody was included as negative control that did not neutralize any 
of the DENV strains. The pAbs raised against DENV-1 antigenic proteins did not block 
DENV-2 infections even at increased serum concentration (1:40) (data not shown). 
These results suggest that the pAbs generated using the recombinant DENV-1 E had 
neutralizing effects by inhibiting D1.59266 and D1.59280 completely and the 
D1.11177, D1.10245 and D1.36000 at varied serum antibody ≥1:180.  
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Table 3.5: Microneutralization and Foci Reduction Neutralization Test50 of polyclonal serum antibodies generated using the DENV-1 
recombinant E 
 
 
 
 The microneutralization and FRNT results are presented as (microneutralization/FRNT50) 
 Microneutralization results are presented as highest titre of serum dilution 
 FRNT50 presented as percentage of foci formed corresponding to the highest titre of pAb observed in microneutralization 
 Polyclonal serum antibody was generated in mice following inoculation with respective recombinant DENV E 
                                              E domain 
Strain 
EDI EDII EDIII  
Polyclonal serum pAb.D1wt pAb.rE171 pAb.rE272 pAb.rE305 pAb.rE390 Genotypes 
       
D1.59266/87 1:320/1 1:640/0 1:320/6 1:640/0 1:640/6 GIII 
D1.59280/87 1:640/7 1:320/1 1:320/5 1:640/0 1:320/1 GIa 
D1.10245/97 1:80/23 1:80/10 >1:80/10 >1:80/5 >1:80/19 GII 
D1.11177/97 1:160/26 1:160/23 1:320/16 1:320/14 1:320/12 GIb 
D1.36000/05 1:160/22 1:320/4 1:640/7 1:640/6 1:640/12 GIc 
D2.16041 >1:20/100 >1:20/97 >1:20/95 >1:20/100 >1:20/100 Asian I 
D2.1704378 >1:20/98 >1:20/97 >1:20/89 >1:20/97 >1:20/99 Cosmopolitan 
-ve control <1:20/00  <1:20/00 <1:20/00 <1:20/00 <1:20/00  
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Figure 3.10. FRNT50 of mouse pAb against dominant DENV-1: The graph explains the 
Foci Reduction Neutralization Test as presented in Table 3.5. The results correspond to 
the pAb titre observed in microneutralization assay. The bars represent the percentage in 
total number of foci and expressed as reduction in foci count. 
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In the following study the binding inhibitory studies of pAb to block dominant DENV-2 
strains in Malaysia was investigated. DENV-1 was used to serve as control and look for 
any cross-reactivity against DENV-2 pAbs. Results shown in Table 3.6 suggests that the 
pAb.D2wt, pAb.rE52 and pAb.rE71 from EDII could not block or neutralize the Asian I 
strains. The pAb.rE164 and pAb.E176 all on EDI failed to neutralize virus at any given 
concentration. The pAbs generated against the EDII and EDIII domain of the mutated E 
of DENV-2 neutralized and blocked infection of all dominant Cosmopolitan strains 
(Table 3.6). The titre varies across pAbs as well as between the strains ranging from 
1:80 to 1:320.  
 
In the Focus Reduction Neutralization Test performed using Vero cell lines, the 
following results when compared with the microneutralization were observed as shown 
in Table 3.6 and Figure 3.11. The reduction in the number of foci is equivalent to two-
fold reduction of the virus titre in the presence of all the pAbs (FRNT50) corresponding 
to the highest titre of pAb observed in microneutralization. The average neutralizing 
dilution of all the Cosmopolitan DENV-2 strains was in the range of 1:80 – 1:320 
accordingly. The percentage of the total foci formed at the minimum dilution of 1:320 
obtained from microneutralization varies slightly across antigenic domains (Table 3.6) 
(Figure 3.11).  An unrelated polyclonal serum antibody included as negative control did 
not neutralize any of the DENV strains. The polyclonal antibody generated against 
DENV-1 antigenic proteins failed to block DENV-2 infections even at increased serum 
concentration. These results suggest that the pAbs recognizes sites on DENV-2 EDII 
and EDIII domains of E consisting of antibody neutralizing sites of the Cosmopolitan 
strains and EDIII for the Asian I strain. No cross-reactivity of the antibody against 
DENV-1 was observed. The results suggest the neutralizing influence of the pAb from 
both DENV-1 (Table 3.5) and DENV-2 (Table 3.6) are type-specific.  
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Table 3.6:  Microneutralization and Foci Reduction Neutralization Test50 of polyclonal serum antibodies generated using the DENV-2 
recombinant E 
 
 The microneutralization and FRNT results are presented as (microneutralization/FRNT50) 
 Microneutralization results are presented as highest titre of serum dilution 
 FRNT50 presented as percentage of foci formed corresponding to the highest titre of pAb observed in microneutralization  
 Polyclonal serum was generated in mice following inoculation with the respective recombinant DENV E 
 
 
                            E domain  
Strain 
EDI EDII EDIII  
Polyclonal 
serum 
pAb.D1wt pAb.rE164 pAb.rE176 pAb.rE52 pAb.rE71 pAb.rE335 pAb.rE393 Genotypes 
         
D2.14245/97 >1:80/33 <1:20/84 <1:20/79 >1:320/23 >1:320/48 >1:320/39 >1:320/32 Cosmopolitan 
D2.14281/97 1:160/47 <1:20/79 <1:20/78 1:160/77 1:320/52 1:320/19 1:320/12 Cosmopolitan 
D2.16041/98 >1:20//88 <1:20/85 <1:20/94 <1:20/78 <1:20/79 1:80/8 1:80/5 Asian 1  
D2.1704378/
07 
>1:80/69 <1:20/75 <1:20/86 >1:320/43 >1:320/49 >1:320/28 >1:320/32 Cosmopolitan 
D2.1877347/
07 
>1:80/23 <1:20/68 <1:20/79 >1:320/21 >1:320/45 >1:320/6 >1:320/4 Cosmopolitan 
D1.59280/87 <1:20/92 <1:20/95 <1:20/93 <1:20/88 <1:20/100 <1:20/100 <1:20/100 GIc 
D1.36000/05 <1:20/95 <1:20/92 <1:20/92 <1:20/89 <1:20/100 <1:20/93 <1:20/97 GIa 
-ve control <1:20/00 <1:20/00 <1:20/00 <1:20/00 <1:20/00 <1:20/00 <1:20/00  
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Figure 3.11. FRNT50 of mouse pAb against dominant DENV-2: The graph explains the 
foci reduction neutralization test as presented in table 3.6. The results correspond to the 
pAb titre observed in microneutralization assay. The bars represent the percentage in 
total number of foci and expressed as reduction in foci count.  
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3.3.2 NEUTRALIZATION ESCAPE MUTANT 
Almost all the pAbs generated against the mutated DENV-1 E neutralized and blocked 
D1.11177, D1.10245, and D1.36000. In addition, the pAb that recognized sites on EDII 
and EDIII of DENV-2 neutralized all the Cosmopolitan DENV-2 strains. However, 
pAb.rE335 and pAb.rE393 have potential neutralizing activity against the dominant 
DENV-2 of Asian I origin. The potential mutation sites on E that are likely to promote 
antibody neutralization were investigated. DENV-1 and DENV-2 virions were 
propagated three times in the presence of the pAb diluted at 1:80 dilutions (highest 
achievable dilution observed in microneutralization test) in C6/36 and Vero cells. Focus 
formation assay was performed at every round of passages, and the foci reduction was 
quantified following the fourth round of passage. The nucleotide sequences of the virus 
tested were also determined after the fourth passage.  Out of the three DENV-1 strains 
tested, the neutralization of D1.10245 was consistent in the presence of all pAb tested 
except for pAb.rE272, in which the foci number increased steadily after the fourth 
passage (Figure 3.12A). D1.11177 also exhibited large increase in foci number above 
the FRNT50 in the presence of the pAb.rE272 (Figure 3.12A). It also showed slight 
increase in foci number in the presence of the pAb.rE171 and pAb.rE305 and remain 
steady at passage four. However, in the presence of pAb.D1wt and pAb.rE390 the foci 
number remained consistently below the FRNT50. D1.36000 foci formation remained 
stable after fourth passage below the FRNT50 (Figure 3.12A). A steady increase was 
observed in the presence of pAb.rE305 but still below FRNT50. These results suggest 
that the viruses D1.10245 and D1.11177 have potential to escape neutralization in the 
future in the event of mutation at rE272, with D1.11177 more likely than the remaining 
two dominant strains. No statistically significant differences were observed between 
infection of C6/36 and Vero cell lines (Figure 3.12A/C). 
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DENV-2 was serially propagated in sub neutralizing antibody concentration (1:80). 
After fourth round of propagation, reduction in foci formed was observed for virus 
propagation in the pAb.D2wt across the Cosmopolitan and Asian I strains.  A steady 
increase in focus formation numbers in the two cosmopolitan strains D2.14245 and 
D2.1877347 was maintained in the presence of the entire polyclonal antibody tested 
except pAb.rE52 and pAb.rE71. There was gradual increase in focus formation with 
every increase of serial passage of the viruses (Figure 3.12B).  At passage 1 through 4, 
two-fold linear increase was observed in the presence of pAb.rE335 and pAb.rE393. 
These results suggest the mutation in E52 and E71 of the EDII would likely enable the 
Cosmopolitan strain to escape neutralization in future than mutation in EDIII. No 
statistically significant differences were observed between infection of C6/36 and Vero 
cells (Figure 3.12B/D). Collectively, the antibody neutralization result from DENV-1 
and DENV-2 from above suggest that mutation at EDII of the respective DENV could 
confer more fitness advantage for the circulating dominant DENV to emerge in the 
future. The exception is the Asian I strains which is likely to emerge because of 
mutation in both EDII and EDIII with EDII showing more likely possibility.   
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Figure 3.12. Selections of DENV-1 and DENV-2 neutralization escape after serial 
propagations in polyclonal sera. The neutralizing potential immune escape strains were 
propagated in C6/36 (A/C) and Vero cell (B/D) lines in the presence of pAb at 
neutralizing titre of 1:80. The * denotes antibody escape after fourth round. The values 
shown are means of duplicate assays.  Foci counts were expressed as percentage.  
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3.3.3 ADAPTATION OF THE NEUTRALIZATION ESCAPE MUTANT IN C6/36 AND VERO 
CELLS 
The DENV-1 and DENV-2 strains that showed an increase in the number of foci after 
serial propagation in the pAb were cultured in alternating C6/36 and Vero cell lines to 
mimic mosquito and human cycle in the presence of pooled pAb from EDII 
(pAb.rE272) and EDIII (pAb.rE305 and pAb.rE390) of DENV-1 and from EDII 
(pAb.rE52, pAb.rE71) and EDIII (pAb.rE335 and pAb.rE393) of DENV-2. All the 
DENV-1 strains tested displayed a fluctuating pattern of higher foci number in C6/C36 
cells and lower foci number in Vero cells (Figure 3.13). The ability of the virus strains 
to grow differently in the two alternating host may be an attribute for adapting to 
different receptors on the cell surfaces.  
 
However, in DENV-2 the titre of the dominant strains maintained in the two cells 
remained steady after the fourth passage except D2.1877347 which shows a slight 
fluctuation in the foci formation at passage three and four. The results therefore 
suggested that DENV-1 alternating between two different hosts adapt differently, and 
the replication efficiency varies according to the host irrespective of the strain. Analysis 
of nucleotide and deduced amino acid of the E sequence from the viruses revealed 
sequence conservation of all the DENV-1 and DENV-2 propagated in the presence of 
pAbs. Silent nucleotide substitution at position 690 (A – T) of the Asian I strain of 
DENV-2 was observed at passage 4. This finding suggests that DENV E alone may not 
play a major role in the dominant endemic virus ability to adapt to different hosts.  
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Figure 3.13. The mosquito and human cycle adaption of DENV-1 and DENV-2 strains. 
Foci formation assay of the DENV-1 and DENV-2 dominant viruses after alternating 
passage between C6/36 and Vero cell lines with pooled ED II and ED III antibody titre 
(1:80) of the respective strains. 
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Nucleotide substitution observed at position 690 of the DENV-2 Asian I strain in Malaysia after serial propagation 
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3.3.4 LOCATION OF MAJOR AMINO ACID USED IN THIS STUDY 
Using the crystal structure of DENV-2 all the six substitutions identified to be 
associated with the emerging antigenic variable strains of the dominant DENV-1 and 
DENV-2 in Malaysia were located. Because the relative distance of antigenic 
determinants to one another correlates with ability of neutralizing antibody to have 
access, their relative positional influences on the monomeric and homodimeric protein 
were highlighted. As shown in Figure 3.14A/B, amino acid residue E161, E171 and 
E297 are located on EDI, E272 on EDII and E305 and E390 on EDIII of DENV-1.  The 
substituted amino acids, E164 and E176 are located in EDI, E52 and E71 in EDII, E335 
and E393 on EDIII of DENV-2 E accordingly. The molecular relative distance observed 
on the amino acid residues on EDI of DENV-1 was 10.05-25.8Å.The two amino acids 
on EDIII were separated apart by 18.07Å. The closest of the EDI and EDIII to amino 
acid residue E272 on EDII was 20.43Å and 36.6Å respectively. In DENV-2, the relative 
distances between the two amino acids residues on the same domain was 21.24Å on 
EDI, 47.45Å on EDII and 22.63Å on EDIII. The relative distances among the residues 
of different antigenic domains on DENV-2 were EDI - EDII 18-35.11Å, EDII – EDIII 
40.49-64.3Å and EDI – EDIII 34.04-51Å accordingly. These results showed the 
position and the proximity of the altered amino acid residues on the exposed surface to 
the monomeric E varies. 
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Figure 3.14. Major amino acid residues substituted on E highlighted in the dimeric 
structure. (A) DENV-1, (B) DENV-2.  The structures were modified based on PDB file 
1OANon FirstGlance program in Jmol version 1.44 
(http://bioinformatics.org/firstglance/fgij/). The dotted lines represent the relative spatial 
distance in Armstrong (Å). 
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3.3.5 THE RELATIVE POSITION AND SIGNIFICANCE OF THE SUBSTITUTED AMINO ACID 
RESIDUES 
The relative positions of amino acid residues on EDI and EDIII, EDI in association with 
EDII of DENV-1 that select for neutralization escape could participate in forming an 
antigenic determinant. The relative distance is within the surface area accessible by the 
neutralizing antibody molecule, 15-20Å × 20-30Å (Figure 3.14A).  Similarly, EDI and 
EDIII together with amino acid residues on EDI (E164) in association with EDII (E52) 
could equally participate in forming an antigenic determinant on both the monomeric 
and homodimeric E of DENV-2 (Figure 3.14B).  The remaining amino acid residues are 
unlikely to form antigenic determinants in association with other amino acid residue 
(relative distance is greater than 30Å).They lie within or adjacent to the antigenic 
determinant accessible by neutralizing antibodies on their own. These results suggest 
that strains with multiple substitutions would likely escape neutralization faster than the 
strains with single mutations. Overall, the amino acids associated with significant 
binding to both mammalian and mosquito cell lines as well as neutralization and 
selection of neutralization escape from dominant DENV-1 and DENV-2 strains are 
highlighted in Figure 3.15. Based on the data reported in this study and their locations 
on the E monomeric protein, the residues are distributed on EDII and EDIII. The 
T272M (DENV-1) and H52K and A71N (DENV-2) residues illustrated in blue, red and 
cyan on EDII influenced neutralization escape. The S390R (DENV-1) and I335L 
(DENV-2), and K393M (DENV-2) illustrated by red, pink and yellow colour balls on 
EDIII fall within putative binding sites and the attachments to cells flaviviruses. 
Mutations created at these positions could influence neutralizing antibody binding. 
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Figure 3.15. Location of significant amino acid residues on monomeric E: Positions of 
E amino acid residues substituted on monomeric E structure. The structure was 
modified using SWIS-prot PDB code: 1ok8on First Glance program in Jmol version 
1.44 (http://bioinformatics.org/firstglance/fgij/).These positions and antigenic domains 
are likely to affect future antigenic evolution of DENV-1 and DENV-2 in Malaysia. 
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4.0 DISCUSSION 
The present study hypothesized that the dominant endemic DENV strains may acquire 
the characteristics of minor strains with the ability to escape immunity and perhaps be 
the progenitors of future outbreak. This hypothesis was investigated here and the 
specific amino acid residues that are conceivably involved in the observations are 
further discussed.  Prior to this study, little is known as to how emerging variants of 
DENV-1 and DENV-2 escape neutralization and cause major outbreaks in Malaysia. 
This study identified and described the effect of the variation in single amino acids on 
the antigenic determinants of DENV-1 and DENV-2 in Malaysia. Results presented 
here highlight and detail the effects of these mutations on the antigenic evolutions of 
DENV-1 and DENV-2 in Malaysian natural population. 
The continuous transmission of different DENV serotypes within the Malaysian 
population has led to several major outbreaks (Abubakar and Shafee 2002; AbuBakar et 
al. 2002b; Teoh et al. 2010) and this established DENV with dynamic antigenic 
variation (Abubakar and Shafee 2002; AbuBakar et al. 2002b; Teoh et al. 2010). During 
a 30 year period, a reasonable number of different DENV strains were isolated from 
patients who visited the University of Malaya Medical Centre (UMMC) and were IgM 
positive for DENV infection (Teoh et al. 2010). University of Malaya Medical Centre is 
the largest teaching hospital in the country and a major referral health facility for 
dengue cases. High numbers of dengue cases exceeding 4000 are reported at the 
hospital yearly, especially during dengue outbreaks. Using the DENV isolates retrieved 
from 30 years of dengue activity in the country, the sequencing project in our laboratory 
has generated a nationwide dengue genome database that is easy to access and hence, 
providing an ideal opportunity for us to study the antigenic evolution of DENV.   
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The antigenic recombinant DENV E used in this study was obtained using a non-
denaturing and highly efficient protein extraction formulation for in-culture bacterial 
cell lyses with reduced proteolytic degradation. Hence, the functional and biological 
activity of the conformationally sensitive antigenic determinants was preserved 
(Roehrig et al. 2004; Tripathi et al. 2008). These recombinant proteins were used to 
ensure that the antibody generated from immunized mice is based on the E in its native 
conformation as opposed to the denatured conformation (Serafin and Aaskov 2001; 
Wahala et al. 2012). Furthermore, the binding affinity and specificity of the antibody 
generated against the target protein or cell surface receptors are largely dependent on 
the conformation of the antigen in which the antibody was raised (Roehrig et al. 2004; 
Wahala et al. 2009). Thus, this approach was useful for the specific functional assays 
employed in this study to establish the effects of the altered amino acid residues on the 
antigenic capability of the E, which largely depends on this conformation. Phage display 
system was used here, allowing for the quantitative estimation of direct binding of the 
recombinant E displayed on the g3p minor coat attachment protein to its cellular targets 
which allowed us to determine the effects of the engineered E mutations (Abd-Jamil et 
al. 2008; Hashemi et al. 2010). The intraperitoneal immunization strategy in mice was 
reported to induce strong neutralizing antibodies following inoculation with 
recombinant E (Liu et al. 2010; Liu et al. 2006; Wang et al. 2006). Both mosquito and 
mammalian cell types have different cellular receptors that recognize DENV (Mercado-
Curiel et al. 2006). The ability of DENV E to interact with different cell types during 
attachment is essential for DENV survival (Smith 2012).  
 
Several studies have used binding assay to demonstrate DENV binding to the surfaces 
of mammalian (Vero) (Chen et al. 2003; Hanley et al. 2003; Thaisomboonsuk et al. 
2005) and mosquito (C6/36) cells(Mercado-Curiel et al. 2006; Munoz et al. 1998; Salas-
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Benito et al. 2007). In the present study, we detected differences in the ability of 
specific mutations to affect virus binding to mammalian and mosquito cells. Similarly, 
when the recombinant phage particles were precipitated with pAb generated in this 
study, there was significant reduction in the binding of the recombinant phage particles 
to mammalian and mosquito cell lines depending on the altered residue on the DENVE. 
The effects of the pAb were noticeable in the binding interaction against the dominant 
dengue virions tested. These results are in line with previous reports, suggesting that the 
interaction of the DENV E with the cell surface receptor plays a significant role in 
determining tissue tropism (Rico-Hesse 2003; Thaisomboonsuk et al. 2005).  The 
inability of certain amino acid positions on E to affect virus binding to both the 
mosquito and mammalian cells demonstrated the influence of the altered positions on E 
in viral mediated cell membrane fusion (Martina et al. 2009; Rodrigo et al. 2009; 
Thaisomboonsuk et al. 2005).  
On the other hand, successful transmission of DENV involves virus replication 
alternating between mosquito vector and human hosts (Twiddy et al. 2002a; Twiddy et 
al. 2002b). The virus must be able to recognize cell surface receptors in both cell types. 
Therefore, it is not surprising that the DENV-1 used in this study adapted to the 
mosquito cells faster than mammalian cells when allowed to infect two cell lines in 
alternative succession to mimic the mosquito and human cycle in the presence of sub-
neutralizing antibodies. This result confirmed the previous reports that suggest the cell 
surface receptors used during human infection are different from those used in 
mosquitoes and are independent of the infecting serotype (Smith 2012; 
Thaisomboonsuk et al. 2005). The mammalian cell surface receptor contains sialic acid 
and heparan sulfate, in which the absence of these two molecules in C6/36 cells may 
facilitate receptor binding in mosquito cell (Smith 2012). The repeated passage in 
mammalian cells may select for net positive charge on the E, which favours interaction 
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with the heparan sulfate on mammalian cell surface. The adaption of the virus in sub-
neutralizing concentrations of antibody mimics antigen-antibody interaction, which 
takes place during the viral entry. Antigenic variation of DENV E therefore, is likely to 
occur in mammalian cells due to the variation in antigenic determinants on E that favour 
net positive charge to negative charge residues as influenced by heparan sulfate in the 
cell surface receptor (Smith 2012). Besides, the pre-existing antibody and cross-
neutralizing antibodies against DENV and other flaviviruses in humans, which limits 
DENV replication, are absent in the mosquito cycle. Hence, in the process of adaptation 
to the human host, the virus changes its E antigenic determinant to adjust to the new 
environment while the mosquito transmits it to the next susceptible host. The difference 
between the DENV genotypes, which carries the different residues in the E, in adapting 
to the alternate cell lines was not evident here. Therefore, there may be other genes that 
are not studied here affecting the adaption of DENV in mammalian or insects 
host(Rico-Hesse 2003). 
The dominant strains that had caused major outbreaks were used to help select for 
neutralization escape against the mouse pAbs generated from the altered E. In the 
present studies, amino acid residues on ED II (E272) of DENV-1 and EDII (E52, E71) 
on DENV-2 were surface exposed variable amino acid (Lin et al. 2012; Wahala et al. 
2010). The residues on the E associated with DENV-1 genotype GIb and GII and 
DENV-2 Cosmopolitan and Asian I strain neutralization escape. The EDI/EDII junction 
was reported to influence mouse monoclonal antibody binding. The EDII lateral ridge 
was reported to contain antigenic determinant that recognize type specific neutralizing 
antibodies (Gromowski and Barrett 2007). Polyclonal antibody against altered E272 
resulted in loss of binding to two dominant DENV genotypes D1.59280 and D1.59266 
(GIII). Similarly, the antisera inhibited and neutralized the two DENV-1 genotypes. 
When the sensitive genotypes were selected against the antisera, pAb against E272 
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exhibited reduced activity against D1.10245 (GII) and D1.11177 (GIb) genotypes. The 
remaining polyclonal antibodies generated against the altered positions E171, E305 and 
E390poorly inhibited these viruses. It its evident thatT272S substitution is involved in 
selection of neutralization escape of D1.10245 (GII) and D1.11177 (GIb). The 
remaining residues are essential parts of the antigenic determinants recognized by the 
pAb. Specifically, S305P substitution does not prevent binding but showed a decreased 
infectivity. The residue lies within the hydrophilic residues that are important for 
antibody-antigen interaction. The E272 is within the hydrophobic pocket (268-280 
residues) known to affect membrane fusion (Butrapet et al. 2011). Mutation at this 
position induces conformational change and virus characteristics essential for DENV 
entry (Butrapet et al. 2011). The S305P residue lies within the negatively charged 
putative heparan sulfate binding site (E294-E310) on A-strand of the EDIII. This 
substitution is the major residue that differentiates D1.10245 (GII) and D1.11177 (GIb) 
with D1.36000 (GIa) on E. The hydrophobic nature of the antigenic determinant at this 
position in the presence of nonpolar residue plays a significant role in maintaining 
protein conformation during binding. The serine residue increases the hydrophilic 
pocket of the antigenic determinant around E305 residue. Because of steric hindrance of 
low pH-induced dimeric prefusion rearrangement, EDI and EDIII conformational 
rearrangement might blocks EDII. This prevents EDII raised mouse pAb accessibility to 
the antigenic determinant. This facilitates neutralization escape (Butrapet et al. 2011; 
Chu et al. 2005; Wahala et al. 2010; Wahala et al. 2012). 
In the same way, both cosmopolitan and Asian I genotypes used in the study escaped 
neutralization because of mutation at E52 and E71 of EDII of DENV-2. The 
Cosmopolitan and Asian I differs at position E52 (His-Gln) and E71 (Ala-Glu) in the E. 
The two residues are conserved in the respective Cosmopolitan and Asian I dominant 
strains. These conserved amino acid residues lie within the EDI/EDII interface and 
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internal fusion peptide on EDII (E98 – E110) respectively (Lin et al. 2012). Recently, 
mutation at E52 was reported to alter antigenic structure, and decrease stability that 
affects membrane fusion in DENV-2 (Butrapet et al. 2011). Previously, mutated E52 
was found to alter the structure of a neutralizing antibody epitope in JEV (Nga et al. 
2004) and increase mouse virulence in YFV (Chambers and Nickells 2001). Equally, 
E71 was reported to be associated with neutralization escape mutant in combination 
with other mutations on E of YFV (Vlaycheva et al. 2005). Similar observations were 
made in this study. The studies showed the two residues could form different antigenic 
determinant that could play a role in neutralization antibody escape. Any mutation in 
this region is likely to alter fusion activity and membrane fusion. The mutations on E52 
and E71 on EDII of the two dominant genotypes of DENV-2 in Malaysia are an 
important determinant for DENV-2 neutralization escape. The mutated E52 and E71 
block virus binding to mammalian and mosquito cells when exposed to pAb. The ability 
of the pAb to select these viruses in primary cell lines, suggested that mutation are 
important component of future DENV-2 antigenic evolution. The antisera against 
altered EDIII (E335 and E393) showed moderate effects as observed in DENV-1. Even 
though there was strong binding and neutralizing antibody effects, the antisera failed to 
select neutralization escape mutant in both the Cosmopolitan and Asian I strain used in 
the study. The E335 residue lies adjacent to the neutralization antigenic determinant on 
A-strand (319-333) (Wahala et al. 2010). The E393 is within the Flavivirus virulence 
determinants on the EDIII lateral ridge (383-394) (Howard 2006; Hung et al. 2004). 
Mutation at these positions affects antibody binding, which allows virus attachment to 
cell receptors and possible infection. The ability of the antisera to neutralize both 
genotypes suggests the mutation on the altered protein does not have any effects on the 
two viruses. 
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Previously, it was reported that in vitro analysis is not an ideal model host for in vivo 
DENV infection studies. The uptake mechanism during antibody absorption had been 
proposed for JEV (Butrapet et al. 1998), WNV (Gollins and Porterfield 1986) and in 
DENV (Chen et al. 1996; Crill and Roehrig 2001; Huang et al. 2006). A correlation has 
been found to exist among the three antigenic domains (Alen et al. 2011; Chen et al. 
1996; Mercado-Curiel et al. 2006). In mice, antibodies against EDI antigenic protein 
were reported to be non-neutralizing (Aaskov et al. 1989; Howard 2006; Serafin and 
Aaskov 2001). But antibodies against EDII determinant can either be neutralizing or 
non-neutralizing (Crill and Roehrig 2001). EDIII, on the other hand were reported to be 
associated with host cell binding (Roehrig et al. 1998), and acted as a major site for 
neutralizing antibody activity (Gromowski et al. 2008). In humans, previous studies 
have reported that, polyclonal human antibody may recognize and react to antigenic 
determinant on EDI and EDII better than to EDIII (Wahala et al. 2009).  
 
Previously, immune responses of DENV E generated in BALB/c mice were reported 
(Howard 2006; Serafin and Aaskov 2001). In DENV-1 and DENV-3, less than 20% of 
anti-DENV-1 and DENV-3 were able to neutralize dengue infection. Approximately, 
40% and 80% were reported to neutralize DENV-2 and DENV-4 respectively (Howard 
2006; Serafin and Aaskov 2001; Simantini and Banerjee 1995).  Recent reports showed 
that the most potent neutralizing antibodies are presented on the lateral ridge of EDIII 
(Wahala et al. 2010). In this study, not all the engineered residues influenced the pAb 
neutralizing activity against the dominant strains. The antisera generated from mutated 
E of EDI and EDIII failed to select neutralization escape variants in both DENV-1 and 
DENV-2. Altering the E sequences lead to changes in the conformation of antigenic 
domain of the E. All other residues on the mutant strains are of the wild type strain. The 
mutant may have an altered conformation that presents changes to existing or may have 
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hidden the antigenic determinant. This leads to a varied binding and antibody-antigen 
interaction when presented to the mosquito and mammalian cells (Lin et al. 2012).  
 
This study showed that dominant DENV were sensitive to neutralization by pAb 
developed against E with the acquired characteristics of the minor strains, which co-
circulate along with these dominant strains. Neutralization escape mutants were also 
selected using the pAb with altered EDII E. Previously, antigenic determinants in 
DENV-1 associated with neutralization escape were identified in EDI (E293) and EDII 
(E279) (Aaskov et al. 1989; Howard 2006; Serafin and Aaskov 2001). The same 
antigenic determinant were reported in EDII (69) and EDIII (307 and 311) of DENV-2 
(Lin et al. 1994; Lok et al. 2001), EDIII (E386) of DENV-3, EDII (E95) (Aaskov et al. 
1989) and ED III (E329) of DENV-4 (Howard 2006; Serafin and Aaskov 2001). The 
residues are within or adjacent to the antigenic determinant identified. The pAb were 
derived from non-compromised mice. Therefore, this may not necessarily reflect the 
neutralizing antibody response in humans. The antibody repertoire against different 
DENV genotypes in humans remains unknown. The mechanism by which these 
residues influence antibody and block virus infection is still disputable. However, the 
neutralization is either because of the binding of a single antibody to one antigenic 
determinant or because of binding pAb to multiple antigenic determinants (Burton et al. 
2001). On the other hand, recent studies suggest the humoral response against 
flaviviruses in humans may be directed away from EDIII neutralizing epitopes. During 
DENV infections in vitro, the antigenic determinants are presented in the cell 
endosomes during fusion that allows for antibody binding and blockage of viral entry 
and infection (Allison et al. 2001; Butrapet et al. 2011; Modis et al. 2004; Schibli and 
Weissenhorn 2004).  
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Before this study, little was known as to how newly emerged DENV of DENV-1 and 
DENV-2 escape neutralization and cause major outbreak in Malaysia. Regardless of the 
mechanism, the results presented in this study identified and described the effect of 
antigenic determinant in EDII (E272) and EDIII (E390) of DENV-1.  Equally, similar 
results were identified and described in EDII (E52) and EDIII (E335 and E393) of 
DENV-2. The study showed that DENV-1 and DENV-2 are expected to escape 
neutralization under sub-neutralizing antibody concentration. The result directly 
underlines the effects of these mutations on naturally emerging DENV-1 and DENV-2 
in Malaysian population keeping in mind the current global DENV vaccine strategy. 
Although the proposed dengue vaccines are heterogeneous mixture of viral populations, 
it might likely not work against naturally occurring neutralization escape mutants.  
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CONCLUSION 
In conclusion, this study presents the first attempt to identify and replace the major 
variable, surface-exposed amino acid residues in the E of the dominant DENV-1 and 
DENV-2 strains with that from the co-circulating minor strains in the Malaysian natural 
population. Polyclonal antibodies generated from these mutants E produced markedly 
segregated binding and neutralization specificity against the dominant DENV-1 and 
DENV-2 strains. Specifically, two dominant strains in both DENV-1 and DENV-2 that 
could likely escape neutralization were identified. Overall, the mutations engineered and 
the mouse pAbs generated against the mutated E were grouped into two groups: (i) 
consist of the mutations on E, which reduced antibody binding and neutralizing activity, 
and (ii) mutations on E, which selects for neutralization escape variants. The mutated 
EDII engineered E selects for neutralization escape, while the EDIII neutralized and 
blocks infection in vitro. Going forward, this strategy and with improved design can be 
adopted to predict dengue virus evolution from present to the future in hyperendemic 
countries. In this way, the predicted strain could be beneficial especially to the vaccine 
developers and manufacturers in the future.   
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Research Projects 
 
 
1. Antigenic Evolution of Dengue Virus in Malaysia- Thesis submitted in 
fulfillment of requirement of Doctorate. Completed (Investigator) 
 
Key task: to determine antigenic evolution of dengue virus type 1 and 
type 2 in Malaysia 
 
2. Dengue Genome: Dynamics of dengue virus antigenic epitopes in recurring 
dengue outbreaks, MOSTI-2008-2011, completed (Investigator) 
   
  Key task: Sequencing of dengue virus genome 
 
3. Malaysian Dengue Virus Genome Data Base, with Malaysia Genome Institute, 
University Kebangsaan Malaysia and Quantum Beez SDN BHD, MDeC, 2009-
2011, completed (Investigator) 
   
  Key task: Consultant on management and maintenance of dengue virus 
genome database 
 
4.  Innovative tools and strategies for surveillance and control of dengue (Novel 
diagnostic assay for resource-limited settings), EU-Dengue tools 2011-2014, in 
progress (Investigator) 
   
  Key task: Evaluating dengue virus screening method in resource limited 
environment 
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5. Space crystallization of industrially important proteins on board the Japanese 
experimental module (JEM), MOSTI-2011-2013, in progress (Investigator) 
   
  Key task: Designing, cloning and screening of the antigenic protein 
 
6. Design and construction of DENV epitope driven vaccine, IPPP-2008-2009, 
completed (Co-Investigator) 
   
  Key task: Construction of gene cassettes 
 
 
Workshop and Seminars 
 
1. Workshop on the Laboratory Diagnosis of Dengue: Department of Medical 
Microbiology Faculty of Medicine University of Malaya Malaysia. 9
th
-13
th
 
May 2005 
 
2. Basic SPSS: Data Analysis Workshop: Information Technology Department 
International Islamic University Malaysia. 26
th
 July 2007 
 
 
3. Discovery Studio Workshop: Malaysian Genome Institute Malaysia. 21st – 
25
th
 July 2008 
 
4. Workshop on Protein Modelling: Division of Bioinformatics and 
Biocomputing Institute of Biological Sciences University of Malaya 
Malaysia. 19
th
 – 21st August 2008 
 
5. Confocal and Live Cell Imaging Seminar: NIKON and micro Lambda 
Malaysia. 28
th
 August 2008 
 
6. Pathway Studio Enterprises Workshop: Institute of Biological Sciences 
University of Science Malaysia.3
rd
 – 7th November 2008 
 
7. Genome Informatics: Malaysian Genome Institute Malaysia. 15th – 19th 
December 2008 
 
8. Applied Biosystems 3730xl Genetic Analyzer Operational Training: 
Annalisa Resources and Applied Biosystems. 6
th
 – 9th January 2009 
 
9. UK-Malaysia Symposium on Current Strategies in Antimicrobial 
Therapeutics: British High Commission Malaysia and Tropical Infectious 
Disease Research and Education Centre University of Malaya Malaysia. 18
th
 – 
19
th
 March 2009 
 
10. 3rd Regional Conference on Molecular Medicine: Genomics, Proteomics 
and the Omics; Reality vs Dreams. Institute for Research in Molecular 
Medicine University of Science Malaysia. 2
nd
 – 4th May 2009  
 
11. Colloquium on Dengue and Arbovirus Research in Malaysia: Tropical 
Infectious Disease Research and Education Centre University of Malaya 
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Malaysia. 12
th
 – 13th April 2010 
 
12. ESCO Biotech Training Workshop: Laminar Flow and Biosafety Cabinet 
Technology and Fume Hood Awareness. ESCO Biotechnology Equipment 
Division and MATRIOUX. 12
th
 May 2010 
 
13. 25-Hours Molecular Research Laboratory Biosafety Training Program: 
Tropical Infectious Disease Research and Education Centre University of 
Malaya Malaysia. 14
th
 – 25thSeptemeber 2010 
 
14. 15th International Congress on Infectious Diseases: Internal Society of 
Infectious Diseases. 13
th
 – 16th June 2012 
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